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3ABSTRACT
Steroids,  vitamin  D  and  oxysterols  are  all  part  of  a  bigger  group  of  com-
pounds  called  lipids,  which  are  generally  important  in  the  function  of  the
human body. Steroids, vitamin D and oxysterols are present throughout the
human body in a broad range of concentrations. In many cases the monitor-
ing  of  these  analytes  can  be  of  high  value.  Therefore,  the  development  of  a
sensitive  and  universal  method,  suitable  for  the  simultaneous  analysis  of
these compounds, is of a great importance. Methods developed for the analy-
sis  of  these compounds have to be highly selective and sensitive,  which is  a
remarkable analytical challenge. The tremendous number of compounds and
the complexity of different biological matrixes are also challenging for ana-
lysts.
In  this  study,  the  goal  was  to  develop  and  test  new  mass  spectrometry
based  methods  for  analyzing  steroids,  vitamin  D  and  oxysterols.  First,  the
feasibility of capillary liquid chromatography-microchip atmospheric pres-
sure photoionization-tandem mass spectrometry (capLC-µAPPI-MS/MS)
was examined for the analysis of anabolic steroids in human urine. The urine
samples were enzymatically hydrolysed and the compounds were liquid-liq-
uid extracted with diethyl ether. The capLC-µAPPI-MS/MS method showed
good sensitivity, linearity and repeatability and the results demonstrate that
the microchip APPI combined with capLC-MS/MS potentially provides a new
method for analyzing non-polar and neutral compounds in biological sam-
ples.
Second, a microfluidic-based liquid chromatography-electrospray ioniza-
tion-mass  spectrometric  system  (HPLC-Chip/ESI/MS)  was  studied  and
compared to a conventional narrow-bore liquid chromatography-elec-
trospray/mass spectrometric system (LC-ESI/MS) for the analysis of ster-
oids. The limits of detection for oxime derivatized steroids, expressed as con-
centrations, were slightly higher with the HPLC-Chip/MS system, which used
an injection volume of 0.5 µL than with the conventional LC-ESI/MS, which
used  an  injection  volume  of  40  µL.  When  the  limits  of  detection  are
expressed as injected amounts, however, the sensitivity of the HPLC-
Chip/MS  system  was  about  50  times  higher  compared  to  the  conventional
LC-MS  system.  The  results  clearly  indicate  that  the  use  of  the  HPLC-
Chip/MS system for the analyses of low-volume samples is advantageous.
Additionally, the feasibilities of the HPLC-Chip/MS system in the analyses of
non-derivatized and oxime derivatized steroids were compared and the
HPLC-Chip/MS method developed for the non-derivatized steroids was suc-
cessfully used in the quantitative analysis of 15 mouse plasma samples.
An  ion  mobility  mass  spectrometry  method  using  a  compact  traveling
wave cell (TWIM-MS) was developed for the separation of steroid isomers in
addition to the miniaturized analytical methods. Three steroid isomer pairs
4were analyzed in their native form and as their p-toluenesulfonyl isocyanate
derivatives. The native steroids were separated from each other, but no sepa-
ration  could  be  attained  for  the  isomers.  The  derivatized  steroid  isomers
were, however, properly separated by TWIM-MS with peak-to-peak resolu-
tions close to or as high as baseline resolution. In conclusion, the developed
TWIM-MS method provides a reliable, fast and repeatable method for sepa-
rating derivatized steroid isomers.
Finally, an ultra-high-performance liquid chromatography-atmospheric
pressure photoionization-tandem mass spectrometric (UHPLC-APPI-
MS/MS) method was developed for the simultaneous quantitative analysis of
several oxysterols and vitamin D related compounds in mouse brain and cell
line samples. An UHPLC-APPI-high resolution mass spectrometric (UHPLC-
APPI-HRMS)  method  was  developed  for  confirmatory  analysis  and  for  the
identification of non-targeted oxysterols. Both developed methods showed
good quantitative  performance  and  APPI  also  provides  high  ionization  effi-
ciency for oxysterols and vitamin D related compounds without the time con-
suming derivatization step needed in the commonly used ESI. Several oxys-
terols were quantified in the mouse brain and cell line samples. Additionally,
25-hydroxyvitamin D3 was  detected  in  mouse  brain  samples  for  the  first
time.
In  conclusion,  the  methods  developed  throughout  this  work  are  highly
sensitive and selective new methods for the analysis of the selected lipids
from biological samples. These methods provide new insights in the analysis
of steroids, vitamin D related compounds and oxysterols, and with some ad-
ditional development some of these presented methods could be imple-
mented in routine laboratories such as those that conduct forensic or doping
analysis.
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GENERAL ABBREVIATIONS
As peak asymmetry factor
AAS anabolic androgenic steroids
APCI atmospheric pressure chemical ionization
APPI atmospheric pressure photoionization
CapLC capillary liquid chromatography
CE collision energy
CYP cytochrome P450
dc direct current
ECD electron capture detector
EI electron ionization
ELISA enzyme-linked immunosorbent assay
ESI electrospray ionization
eV electron volt
FID flame ionization detector
GC gas chromatography
GC-MS gas chromatography-mass spectrometry
GP Girard P hydrazine
HMP 2-hydrazino-1-methylpyridine
HPLC high performance liquid chromatography
HRMS high resolution mass spectrometry
i.d. internal diameter
IMS ion mobility spectrometry
IMS-MS ion mobility spectrometry mass spectrometry
ISTD internal standard
LC liquid chromatography
LC-MS liquid chromatography-mass spectrometry
LLE liquid-liquid extraction
LOD limit of detection
LLOQ lower limit of quantitation
LOQ limit of quantitation
m/z mass-to-charge ratio
MS mass spectrometry/mass spectrometer
MS/MS tandem mass spectrometry
NFPH 2-nitro-4-trifluoromethylphenylhydrazine
NMR nuclear magnetic resonance
PBS phosphate buffered saline
PTAD 4-phenyl-1,2,4-triazoline-3,5-dione
R2 coefficient of determination
Rp-p peak-to-peak resolution
RIA radioimmunoassay
RP-LC reversed phase liquid chromatography
12
rpm rounds per minute
%RSD relative standard deviation
S/N signal-to-noise ratio
SPE solid-phase extraction
SRM selected reaction monitoring
TMS trimethylsilyl
tR retention time
TWIM traveling wave ion mobility
TWIM-MS traveling wave ion mobility mass spectrometry
UHPLC ultra-high-performance liquid chromatography
UV ultraviolet
Wb peak width
Wh peak half-width
WT wild type
µAPPI microchip atmospheric pressure photoionization
13
ABBREVIATIONS OF ANALYTES
A aldosterone
AN androstenedione
AND or 3α-AN androsterone
D3 cholecalciferol
d3-D3 d3-cholecalciferol
CORT corticosterone
CS cortisone
7-DHYD 7-dehydrocholesterol
DHEA dehydroepiandrosterone
11-DC 11-deoxycortisol
DESMO desmosterol
DHT dihydrotestosterone
1α,25-D3 1α,25-dihydroxycholecalciferol
17-MDN 17-epimetandienone
17α-T epitestosterone
D2 ergocalciferol
α-ES α-estradiol
β-ES β-estradiol
ES estrone
HC hydrocortisone
25-OH-D3 25-hydroxycholecalciferol
7α-OH-Chl 7α-hydroxycholesterol
7β-OH-Chl 7β-hydroxycholesterol
22-OH-Chl 22(S)-hydroxycholesterol
24-OH-Chl 24(S)-hydroxycholesterol
27-OH-Chl 27-hydroxycholesterol
d6-27-OH-Chl d6-27-hydroxycholesterol
17-OH-PREG 17-hydroxypregnenolone
17-OH-PROG 17-hydroxyprogesterone
7-OXO 7-ketocholesterol
NANm metabolite of nandrolone
MTS methyltestosterone
NAN nandrolone
PREG pregnenolone
PROG progesterone
T or 17β-T testosterone
d3-T d3-testosterone
3β-AN trans-androsterone
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1 REVIEW OF THE LITERATURE
Steroids,  vitamin  D  and  oxysterols  are  all  part  of  a  larger  group  of  com-
pounds called lipids. Generally, lipids are defined as naturally occurring
small compounds, which are readily soluble in organic solvents.1,2 Lipids are
also  important  in  the  function  of  the  human body  and  also  other  biological
systems.2 Steroids  are  involved  in  the  regulation  of  central  metabolic  path-
ways, energy metabolism, water and salt balance, and behavioral and cogni-
tive functions.3-11 Additionally,  some  steroids  can  serve  as  doping  agents  in
sports due to their anabolic effects on muscle and muscle strength.12-15 Vita-
min D and its metabolites and oxysterols, on the other hand, are known to be
involved  in  several  diseases,  such  as  bone  metabolic  diseases,  certain  can-
cers, autoimmune diseases and neurodegenerative diseases.16-26 Therefore,
these compounds are routinely analysed in biological samples in analytical
laboratories  all  over  the  world.  The  concentrations  of  the  selected  com-
pounds  in  biological  samples  can,  however,  be  very  low.  Thus,  in  order  to
achieve  correct  information  about  these  compounds  in  the  human  body,
more sensitive and specific analytical methods are constantly needed.
This  literature  review  focuses  on  the  physiology  of  the  selected  lipids  in
the human body and it also summarizes the most important analytical meth-
ods used for the analysis of these compounds in biological samples.
1.1 SELECTED LIPIDS AND THEIR PHYSIOLOGY IN THE
HUMAN BODY
1.1.1 STEROIDS
Steroid hormones are synthesized from cholesterol by a series of enzymatic
reactions  mainly  in  the  adrenal  glands  and  the  gonads,  and  in  the  human
feto-placental unit.7,27,28 The  steroid  structure  is  based  on  a  tetracyclic  ring
structure with different substituents that specify the steroid. Steroids are
further divided into subclasses based on the number of carbon atoms present
in the molecule: estrane (C18), androstane (C19), pregnane (C21), cholane
(C24), and cholestane (C27).29 The structure of the subclasses and the steroid
nomenclature are shown in Figure 1.
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Figure 1 Structures of the steroid subclasses and the steroid nomenclature as identified by
letters and numbers of carbon atoms. Adapted from Makin et al.29
It is common that the A or B ring of the steroid structure contains a dou-
ble  bond  and  that  there  are  substituents  including  hydroxyl  groups  and/or
carbonyl groups present at positions C-1, C-3, C-7, C-11, C-12, C-17, C-21,
and/or C-25.29 Steroids also have several chiral centers that lead to as many
as 64 different stereoisomers with their substituents either above or below
the  molecular  plane  (α-  or  β-configuration).29 It  has  been  shown  that  the
“bent” steroid ring structure associated with β-isomers may have signifi-
cantly  different  biological  effects  in  the  human body  compared  to  the  more
planar ring structure in α-isomers.30,31
Steroids can also be classified according to their biological activities. The
most important steroid classes in this classification system are glucocorti-
coids,  mineralocorticoids,  sex  steroids  (androgens  and  estrogens)  and  vita-
min D-derived hormones.7,27,28 The  physiological  significance  of  steroids  is
exemplified by their participation in the regulation of various central meta-
bolic  pathways,  including reproductive functions,  energy metabolism, water
and salt balance, and behavioral and cognitive functions.3-11 The concentra-
tions of many steroids vary considerably during different stages of life, which
include  age,  stage  of  pregnancy,  menstrual  cycle,  illness,  and  various  drug
treatments.32-37 Consequently,  the amount of  steroids present in the human
body is a valuable tool inter alia for clinical studies and for the diagnosis of
endocrine disorders.3,32-37
Some steroids, namely the anabolic androgenic steroids (AAS), also serve
as doping agents in sports due to their positive effect on muscle strength.12-15
The use of these testosterone derivatives in sports was banned in 1976.12,14
They are, however, also used in clinical practice for the treatment of different
diseases and symptoms.13,38
Review of the literature
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1.1.2 VITAMIN D
Vitamin  D  exists  naturally  either  as  vitamin  D2 or  as  vitamin  D3 (Figure
2).16,29 Mushrooms are a rich source of D2,  whereas fish are a rich source of
D3.16,18,39-41 Vitamin D3 is additionally biosynthesized in the skin from its pre-
cursor 7-dehydrocholesterol upon exposure to ultraviolet (UV) light (Figure
3).  Vitamin  D2,  on  the  other  hand,  is  supplied  only  from dietary  sources  or
from supplements.42
Vitamin  D  as  such  is  biologically  inactive  and  it  is  hydroxylated  in  the
liver to 25-hydroxyvitamin D (25-OH-D), which is the major circulating form
in the body.17-19,29,39,40,43,44 The resulting 25-OH-D is then further metabolized
in  the  kidney  to  the  biologically  active  form  1α,25-dihydroxyvitamin  D
(1α,25-OH-D). Additionally numerous other metabolites of vitamin D have
been well known for decades and the metabolism route has previously been
thoroughly presented.17,29,43,44 Figure 3 illustrates the biosynthesis of vitamin
D3 and the formation of the most important metabolites of vitamin D3.
Vitamin  D  is  well  known  for  its  importance  in  various  functions  in  the
human body and vitamin D deficiency or insufficiency has long been known
to be a risk factor for bone metabolic diseases, such as rickets, osteomalacia,
and osteoporosis.16-19 It  has  also  been  shown,  that  vitamin  D  deficiency  is
involved  in  other  diseases  such  as  certain  cancers  (for  example  leukemia),
autoimmune diseases and neurodegenerative diseases.18,20-24
Figure 2 Structures of vitamin D2 and D3.
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Figure 3 Biosynthesis of vitamin D3 and formation of the most important metabolites of vita-
min D3.
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1.1.3 OXYSTEROLS
Sterol  lipids  such  as  cholesterol  and  its  derivatives  are  important  compo-
nents of membrane lipids.45 Cholesterol is the precursor of the hormonal
steroids  and  bile  acids,  and  it  can  be  found  at  high  concentrations  in  the
blood, brain and other steroidogenic tissues.46,47 Cholesterol is also the start-
ing material for the formation of oxysterols (Figure 4).46,48,49 Oxysterols can
be formed enzymatically by several different cytochrome P450 (CYP) en-
zymes in phase I metabolism of cholesterol and/or directly from cholesterol
by reactive oxygen species.
Recently,  oxysterols  have  been  shown  to  be  biologically  active  mole-
cules.26,46,50-52 Structurally different oxysterols have differing biological activ-
ity whereas the same oxysterols might even have different activities in differ-
ent cells.46 There is also evidence of changes in the concentrations of oxyster-
ols as a result of neurodegenerative diseases.25,26
Figure 4 Formation of oxysterols from cholesterol by CYP enzymes or by reactive oxygen
species [O]. Adapted from Griffiths et al.46
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1.2 ANALYSIS OF STEROIDS, VITAMIN D AND
OXYSTEROLS OF BIOLOGICAL SAMPLES
Steroids,  vitamin  D and  oxysterols  are  present  throughout  the  human body
in a broad range of concentrations (from pg mL-1 to µg mL-1 depending on the
compound).53-55 In many cases the monitoring of these analytes can be highly
significant  such  as  in  doping  analysis  and  in  the  diagnostics  of  diseases.
Therefore, the development of universal methods suitable for the simultane-
ous analysis of these compounds is of great importance. Methods developed
for the analysis of these compounds have to be highly selective and sensitive,
which sets a remarkable analytical challenge for analytical chemists. Also the
tremendous amount of compounds and the complexity of different biological
matrixes are challenging. Nevertheless, these classes of compounds have
been  detected  and  analysed  in  biological  samples  for  a  long  time  and  the
sample preparation procedures and analytical methods are constantly being
updated.
1.2.1 SAMPLE PREPARATION
Analysis of the selected lipids (steroids, vitamin D and oxysterols) in biologi-
cal  samples  usually  requires  some  kind  of  sample  pretreatment  or  sample
cleanup before the actual analysis step. This is largely because there are a lot
of  compounds  (e.g.  other  lipids)  present  in  the  biological  matrix,  and  these
might interfere with the determination of the targeted analytes. In some
cases  the  compounds  of  interest  exist  in  the  biological  samples  mainly  as
their metabolites such as steroid glucuronides in urine samples,56,57 or both
as metabolites and as the native compounds. Thus, an enzymatic hydrolysis
step is required prior to the actual sample cleanup in order to be able to ana-
lyse the total amount of these compounds present in the biological samples.
Sometimes a fast protein precipitation step might be enough for cleaning
up the sample,56,58-63 but usually the sample preparation procedures include
the  homogenization  of  the  sample46,64-66 and a liquid-liquid extraction
(LLE)46,56,59-61,64-69 and/or  a  solid-phase  extraction  (SPE)46,56,59-61,64-71 step.
LLE is still widely used, but nowadays other more efficient methods are often
used.68 In  many  cases,  SPE is  considered  superior  to  LLE,  because  a  better
recovery of the analytes from the samples is usually achieved by SPE. SPE is
also  considered  to  be  a  more  green  method  compared  to  LLE,  as  the  con-
sumption of organic solvents is usually lower than when SPE is used.
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1.2.2 ANALYTICAL METHODS
The compounds included in the lipid classes investigated in this study affect
many  of  the  functions  of  the  human  body.  Therefore,  the  determination  of
changes  in  the  concentrations  of  these  compounds  in  different  biological
samples can be used as a tool  for example in the diagnostics  of  several  dis-
eases. Several analytical methods have been proposed for these analyses.
Table 1 show some examples of previously proposed methods and this liter-
ature review focuses on the most important of the methods hitherto used.
1.2.2.1 Immunoassays
Immunological  methods  have  for  years  been  widely  used  in  the  analysis  of
steroids,  vitamin  D  related  compounds  and  oxysterols  in  biological  sam-
ples.72-76 The most common methods are based on radioimmunoassays (RIA)
or enzyme-linked immunosorbent assays (ELISA).74-76 The advantage of  us-
ing  immunological  methods  is  that  they  can  allow for  a  high  throughput  of
samples.73,74 The suitability  of  immunoassays in the analysis  of  complicated
biological samples is, however, questionable due to matrix effects and possi-
ble cross reactions.72-74 Nevertheless, these methods are still in widespread
use especially in clinical laboratories.77,78
1.2.2.2 Gas chromatography-mass spectrometry
There are some examples of analytical methods that utilize conventional gas
chromatography  (GC)  with  a  flame ionization  detector  (FID)  or  an  electron
capture detector (ECD) for determining the concentration of selected lipids
in biological samples.46,79,80 However,  since  the  coupling  of  gas  chromatog-
raphy to mass spectrometry (GC-MS) in the mid-1960s, this latter combina-
tion has been the preferred configuration for the analysis of the selected li-
pids.29,67,79,81-89
A GC-MS that uses electron ionization (EI)  alleviates the concerns faced
about the immunological methods since it provides good chromatographic
resolution combined with high selectivity and sensitivity.85,90-96 Unfortu-
nately  this  method  is  time  consuming,  because  most  compounds  require
derivatization (in order to achieve evaporation of the analytes) prior to analy-
sis.67,79,81,82,90-92,94,96 The most commonly used procedure is  to derivatize the
hydroxyl groups of the analyte to trimethylsilyl (TMS) ethers.67,82,90,91,94,97
Despite the drawbacks of  GC-EI-MS, this  method is  still  considered as a
reference method in steroid and oxysterol analyses.67,92,98
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1.2.2.3 Liquid chromatography-mass spectrometry
The complicated sample pretreatment procedure needed for GC-MS analysis
can be avoided by high performance liquid chromatography (HPLC) methods
(with  UV  detection).  These   have  been  used  in  the  analysis  of  lipids  in
biological samples.44,67,74,80,82,98-101 Nowadays,  the  use  of  liquid  chromatog-
raphy-mass spectrometry (LC-MS) based methods have superseded HPLC-
UV for the analysis of the selected lipids in biological samples.44,46,73,96,100-104
Electrospray ionization (ESI),53,61,67,69,70,105 atmospheric pressure chemical
ionization (APCI),61,67,70,105-107 and atmospheric pressure photoionization
(APPI)62,70,105,108-111 have all been used in the analyses of these selected lipids
in biological samples by LC-MS. ESI has proven to be an appropriate ioniza-
tion technique for polar compounds.112 However, the ionization efficiency of
ESI for non-polar and neutral analytes can be poor.112,113 Moreover, ESI is not
applicable with non-polar mobile phase solvents and it can suffer from sup-
pression caused by high ion concentrations. This limits the use of buffers and
demands careful sample preparation before analysis.112 These limitations
entail that complementary ionization techniques such as APCI and APPI are
used.  APCI  is  more  suitable  for  the  analyses  of  less  polar  compounds  com-
pared to ESI. APCI also allows the use of polar and non-polar solvents, and
tolerates  higher  electrolyte  concentrations.  APPI,  on  the  other  hand,  was
originally developed for the ionization of non-polar compounds, which can
not be ionized by ESI or APCI.113,114 APPI is also suitable for polar compounds
and thus it can be considered a more general ionization method compared to
ESI and/or APCI. In addition, suppression of ionization is significantly less
with APCI and APPI than with ESI.113
The low ionization efficiency of  APCI and ESI for many non-polar lipids
requires different derivatization procedures to be utilized in order to enhance
the ionization efficiency and hence the sensitivity of the meth-
ods.53,61,64,67,69,107,115,116 The most commonly used derivatization reagents for
the derivatization of steroids are hydroxylamine,115,116 dansyl chloride,53,107 2-
nitro-4-trifluoromethylphenylhydrazine (NFPH),117 2-hydrazino-1-
methylpyridine (HMP),64 and  Girard  P  hydrazine  (GP).118 There  are  also
some reports  regarding the less common derivatization reagents,  such as p-
toluenesulfonyl isocyanate (PTSI), for steroids.119,120 The derivatization rea-
gents  used  for  the  derivatization  of  vitamin  D  related  compounds,  on  the
other  hand,  are  slightly  different  from  those  used  for  steroids.  The  most
common derivatization reagents are Cookson-type reagents.54,61 Currently, 4-
phenyl-1,2,4-triazoline-3,5-dione (PTAD) is the only reagent of this kind,
which is commercially available. Oxysterols are also commonly derivatized
for enhanced ionization efficiency.67 The  most  common derivatization  reac-
tions for these steroid-like compounds include the following: the derivatiza-
tion  to  picolinyl  esters,  to  N,N-dimethyl  glycine  esters  or  to  Girard  hydra-
zones. Unfortunately, the derivatization step excludes the development of a
universal analysis method suitable for all of these lipids, since the derivatiza-
tion reaction is usually only possible on specific sites such as the s-cis-diene
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structure in vitamin D related compounds or functional  groups that  include
hydroxyl or carbonyl groups in steroids and oxysterols of the com-
pound.54,61,64,67,117
1.2.2.4 Miniaturized analytical methods
A current trend in analytical chemistry is the miniaturization of conventional
analysis techniques towards lab-on-a-chip devices.121-124 The  purpose  of  the
miniaturization is to achieve rapid and sensitive analyses of very low sample
amounts with minimal solvent and reagent consumption.121,123,124 In addition,
the possibility of automated analysis including all analysis steps i.e. sample
preparation, separation, and detection being integrated on the same micro-
chip is a goal that fascinates scientists.121,122 In the past few years, the use of
MS in microchip analysis has gained wide interest. This is based on the effort
to couple micro- or nanofluidic separation systems to MS, and therefore the
main interest is the miniaturization of ion sources.122,125
Until now, research has focused mainly on ESI, as the flow rates used in
ESI are ideal for microfluidic devices.122,125-127 Today,  there  are  also  some
commercial microchips available for the coupling of low flow rate separation
systems to MS.125,128-133 One of these is the HPLC-Chip/MS system by Agilent
Technolgies.125,128 This  system  integrates  a  sample-enrichment  column,  a
reversed phase LC separation column, and a nanoESI on a single polyimide
chip, which eliminates the need for conventional LC connections.128 The
HPLC-Chip/MS system which is made by Agilent Technologies has most of-
ten been used for the analysis of proteins and peptides,128,134-137 and  to  a
lesser extent for the analysis of anthocyanins138 and saccharides.139,140 The
Waters  Corporation  has  also  developed  a  microchip  based  LC-MS  system
called a NanoTile.129-133 This relatively new device incorporates a reversed
phase  LC  separation  column,  an  electrospray  ionization  emitter  and  all  the
fluidic and electric connections needed. This new device has been used inter
alia for the analysis of drugs133 and proteins.131,132 Both of these commercial
systems have also been used for analyzing steroids in biological sam-
ples.116,129,130
The flow rates used with commercial APCI and APPI ion sources, on the
other hand, are relatively high, typically above 50 µL min-1. This makes these
ion sources incompatible with low flow rate separations. A microfabricated
heated nebulizer chip was introduced in 2004 in order to correspond to the
need  for  low  flow  rate  compatible  APCI  and  APPI  sources.141,142 This  new
microchip was then successfully used as an APCI and APPI source. Since its
original fabrication, the microchip has been refined,143,144 and  used  for  sev-
eral other applications.141,145-156 This  microfabricated  heated  nebulizer  pro-
vides  flow  rates  down  to  50  nL  min-1, excellent sensitivity, robust analysis,
and efficient ionization for neutral and non-polar compounds including ster-
oids.141,145,146,148,150-153,156
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1.2.2.5 Ion mobility spectrometry mass spectrometry
The  techniques  of  ion  mobility  spectrometry  (IMS)  and  ion  mobility  spec-
trometry coupled to mass spectrometry (IMS-MS) have been known for dec-
ades and they have been used in numerous different applications and set-
tings.157-159 The separation that  occurs in IMS-MS is  based on the mass and
the  charge  of  the  analyte  in  addition  to  other  parameters.157,160 These other
parameters include the analyte collision cross section and the molecular in-
teractions with the drift gases of different polarizabilities.
The IMS-MS technique also provides high sensitivity, specificity, and,
most importantly,  analysis  times on a millisecond timescale.  These features
could  be  advantageous  in  the  separation  of  steroid  isomers,  which  is  time
consuming  and  laborious.  The  GC-MS and  LC-MS techniques  are  currently
used for the separation of the α/β isomers of steroids, but unfortunately
these techniques require long chromatographic runs in order to achieve suf-
ficient separation of the isomers. As a result, these otherwise highly sensitive
and specific  approaches  lose  their  suitability  especially  for  high  throughput
routine analysis  and faster methods are needed in order to increase sample
throughput and to decrease costs of analysis.
The development of IMS-MS equipment is becoming more popular
among commercial instrument manufacturers and therefore the availability
of this method is also increasing. IM techniques are also increasingly used in
conjunction with LC-MS,161-163 whereby IM provides an additional  degree of
separation and therefore significantly improved peak capacity and specificity.
This can be particularly beneficial in the analysis of complex biological sam-
ples.162-164 The recently introduced traveling wave ion mobility  (TWIM) also
provides  a  new mode  of  ion  propulsion  and  separation  for  mobility  experi-
ments.165 The  TWIM  device,  when  combined  to  MS  (TWIM-MS),  has  been
shown to  be  a  powerful  tool  in  bioanalysis.  This  is  because  it  provides  high
ion transmission and good separation efficiency especially when using more
polarizable and more massive drift-gases are used.166,167
Although  IMS  and  IMS-MS  are  increasingly  used  in  bioanalytics,  there
are  only  very  few  reports  on  the  analysis  of  steroids  that  use  these  tech-
niques.119,162,163,168,169
Review of the literature
24
Table 1. Examples of methods and achieved sensitivities used in the analysis of steroids, vitamin D and oxysterols. For abbreviations see chapter
Abbreviations.
Method Compounds Matrix LOD/LOQ Reference
LC-MS
based methods
Endogenous steroids (23 analytes) Urine LOQ: 0.3 – 3 ng mL-1 [170]
Prohibited steroids (19 analytes) Urine LOQ: 2 – 15 ng mL-1 [171]
Prohibited doping substances
(137 analytes) Urine LOD: 0.2 – 250 ng mL
-1 [172]
Endogenous steroids (8 analytes) Serum LOQ: 8 pg mL-1 [53]
Vitamin D + metabolites (5 analytes) Serum LOQ: 1 – 2 ng mL-1 [109]
Vitamin D + metabolites (5 analytes) Serum LOQ: 25 pg mL-1 [54]
Vitamin D + metabolites (5 analytes) Serum LOQ: 0.2 – 0.6 ng mL-1 [173]
27-OH-Chl Plasma LOQ: 15 ng mL-1 [108]
4β-OH-Chl Plasma LOQ: 10 nM [110]
25-OH-D3 Cerebrospinal fluid LOQ: 0.04 nM [174]
25-OH-D3 Serum LOQ: 4 nM [174]
GC-MS
based methods
Endogenous steroids (46 analytes) Brain LOD: 0.005-1 ng g-1 [93]
Endogenous steroids (18 analytes) Cerebrospinal fluid +serum
LOD: 0.04 – 1 pM [55]
Anabolic androgenic steroids (6 analytes) Urine LOD: 0.2 – 1 ng mL-1 [146]
RIA Vitamin D metabolites Serum LOD: 2 – 500 pg mL-1 [75]
LC-IMS-MS
based methods
Testosterone glucuronide +
epitestosterone glucuronide Urine LOD: 0.7 – 7.4 ng mL
-1 [162]
Anabolic androgenic steroids (5 analytes) Urine LOD: 50 – 500 pg mL-1 [163]
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2 AIMS OF THE STUDY
The overall aim of this research was to develop several different mass spec-
trometry based methods for the analysis of steroids, vitamin D related com-
pounds and oxysterols, and to apply these developed methods to the analysis
of biological samples.
The  more  detailed  aims  of  the  research  papers,  which  are  included  in  this
thesis (I-IV) are the following:
· to evaluate the feasibility of the recently developed heated nebulizer
microchip  in  APPI  mode,  when  combined  to  capLC-MS/MS,  in  the
analysis of anabolic steroids in human urine samples (I)
· to compare a commercially available HPLC-Chip/ESI/MS system with
a  conventional  LC-ESI/MS  in  the  analysis  of  oxime  derivatized  ster-
oids and to apply the microchip based system to the analysis  of  non-
derivatized steroids in mouse plasma samples (II)
· to apply ESI-TWIM-MS for separating selected non-derivatized and p-
toluenesulfonyl isocyanate derivatized steroid isomers using two diffe-
rent drift gases (N2 and CO2) at different pressures (III)
· to develop and to compare two highly sensitive and selective UHPLC-
APPI-MS  methods  for  the  analyses  of  vitamin  D  related  compounds
and oxysterols in mouse brain samples and cell line samples (IV)
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3 MATERIALS AND METHODS
This section briefly describes the chemicals, samples and sample pretreat-
ment procedures, instrumentation and analytical methods used in this study.
More detailed descriptions can be found in publications I-IV.
3.1 CHEMICALS
The  solvents  used  in  this  study  are  listed  in  Table  2.  All  solvents  were  of
HPLC grade unless otherwise stated.
Table 2. Solvents (with abbreviations) used in the study.
Solvent Manufacturer/Supplier Publi-cation
Acetonitrile (ACN)
Rathburn Chemicals Ltd., Walkerburn,
Scotland
Sigma-Aldrich, St. Louis, MO, USA
Sigma-Aldrich, Steinheim, Germany
(LC-MS grade)
II
III
IV
Dichloromethane
(DCM) Sigma-Aldrich, Steinheim, Germany IV
Diethyl ether
(freshly distilled) VWR, Espoo, Finland I
Isopropanol (IPA)
LC-MS grade Sigma-Aldrich, Steinheim, Germany IV
Methanol (MeOH)
Mallinckrodt Baker B.V., Deventer, The
Netherlands
Sigma-Aldrich, Steinheim, Germany
(HPLC grade and LC-MS grade)
J.T. Baker, Mexico City, Mexico
I, II
II, IV
III
Methyl tertiary-
butyl ether (MTBE) Sigma-Aldrich, Steinheim, Germany II
Toluene
(APPI dopant)
Sigma-Aldrich, St. Louis, MO, USA
Sigma-Aldrich, Steinheim, Germany
I
IV
Water
(milli-Q, H2O)
Millipore, Molsheim, France
Millipore, Billerica, MA, USA
I, II, IV
III
The reagents used in this study are listed in Table 3. All reagents were of
reagent grade unless otherwise stated.
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Table 3. Reagents (with abbreviations) used in the study.
Reagent Manufacturer/Supplier Publi-cation
Ammonium acetate
(NH4Ac)
Sigma-Aldrich, Steinheim,
Germany II
Ammonium hydroxide
(NH4OH)
Acros Organics, New Jersey,
USA III
Bovine serum albumin
(BSA)
Sigma-Aldrich, Steinheim,
Germany II
Formic acid (HCOOH)
Sigma-Aldrich, Steinheim,
Germany (HPLC grade)
Acros Organics, New Jersey,
USA (analytical grade)
II
III
β-Glucuronidase
(from Helix Pomatia,
type HP-2)
Sigma-Aldrich, St. Louis, MO,
USA
I
Hydroxyl amine
hydrochloride
(HPLC grade)
Sigma-Aldrich, Steinheim,
Germany II
Potassium acetate Mallinckrodt Baker B.V.,Deventer, The Netherlands I
Potassium carbonate Mallinckrodt Baker B.V.,Deventer, The Netherlands I
Sodium hydrogen
carbonate
Mallinckrodt Baker B.V.,
Deventer, The Netherlands I
p-toluenesulfonyl
isocyanate (PTSI, 96%)
Sigma-Aldrich, St. Louis, MO,
USA III
The standards (with abbreviations) used in this study are listed in Table 4.
The structures of the studied compounds are shown in publications I-IV.
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Table 4. Standards (with abbreviations) used in the study.
Standard Manufacturer/Supplier
Publi-
cation
Aldosterone (A) Sigma-Aldrich, Steinheim, Germany II
Androstenedione (AN)
Steraloids Inc., Newport, RI, USA
Sigma-Aldrich, Steinheim, Germany
II
Androsterone
Sigma-Aldrich, Steinheim, Germany
(AND)
Sigma-Aldrich, St. Louis, MO, USA
(3α-AN)
II
III
Cholecalciferol (D3)
Enzo Life Sciences Inc.,
Farmingdale, NY, USA
IV
d3-Cholecalciferol (d3-D3) Sigma-Aldrich, Steinheim, Germany IV
Corticosterone (CORT) Sigma-Aldrich, Steinheim, Germany II
Cortisone (CS) Sigma-Aldrich, Steinheim, Germany II
7-Dehydrocholesterol
(7-DHYD)
Sigma-Aldrich, Steinheim, Germany
IV
Dehydroepiandrosterone
(DHEA)
Sigma-Aldrich, Steinheim, Germany
II
11-Deoxycortisol (11-DC) Sigma-Aldrich, Steinheim, Germany II
Desmosterol (DESMO)
Avanti Polar Lipids Inc., Alabaster,
Al, USA
IV
Dihydrotestosterone (DHT) Sigma-Aldrich, Steinheim, Germany II
1α,25-
Dihydroxycholecalciferol
(1α,25-D3)
Sigma-Aldrich, Steinheim, Germany
IV
17-Epimetandienone
(17MDN)
United Medix Laboratories Ltd.,
Helsinki, Finland
I
Epitestosterone (17α-T) Sigma-Aldrich, St. Louis, MO, USA III
Ergocalciferol (D2) Sigma-Aldrich, Steinheim, Germany IV
α-Estradiol (α-ES)
Sigma-Aldrich, St. Louis, MO, USA
Sigma-Aldrich, Schnelldorf,
Germany
III
β-Estradiol (β-ES) Sigma-Aldrich, St. Louis, MO, USA III
Estrone (ES) Sigma-Aldrich, Steinheim, Germany II
Hydrocortisone (HC) Sigma-Aldrich, Steinheim, Germany II
25-Hydroxycholecalciferol
(25-OH-D3)
Sigma-Aldrich, Steinheim, Germany
IV
7α-Hydroxycholesterol
(7α-OH-Chl)
Fountain Limited, Naxxar, Malta
IV
7β-Hydroxycholesterol
(7β-OH-Chl)
Fountain Limited, Naxxar, Malta
IV
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Table 4 continued Standards (with abbreviations) used in the study.
Standard Manufacturer/Supplier
Publi-
cation
22(S)-Hydroxycholesterol
(22-OH-Chl)
Fountain Limited, Naxxar, Malta
IV
24(S)-Hydroxycholesterol
(24-OH-Chl)
AH Diagnostics Oy, Helsinki,
Finland
IV
27-Hydroxycholesterol
(27-OH-Chl)
Santa Cruz Biotechnology Inc.,
Heidelberg, Germany
IV
d6-27-Hydroxycholesterol
(d6-27-OH-Chl)
Avanti Polar Lipids Inc., Alabaster,
Al, USA
IV
17-Hydroxypregnenolone
(17-OH-PREG)
Sigma-Aldrich, Steinheim, Germany
II
17-Hydroxyprogesterone
(17-OH-PROG)
Sigma-Aldrich, Steinheim, Germany
II
7-Ketocholesterol
(7-OXO)
Avanti Polar Lipids Inc., Alabaster,
Al, USA
IV
Metabolite of nandrolone
(NANm)
United Medix Laboratories Ltd.,
Helsinki, Finland
I
Methyltestosterone (MTS)
United Medix Laboratories Ltd.,
Helsinki, Finland
I
Nandrolone (NAN)
United Medix Laboratories Ltd.,
Helsinki, Finland
I
Pregnenolone (PREG) Sigma-Aldrich, Steinheim, Germany II
Progesterone (PROG) Sigma-Aldrich, Steinheim, Germany II, IV
Testosterone
Sigma-Aldrich, Steinheim, Germany
(T)
Sigma-Aldrich, St. Louis, MO, USA
(17β-T)
II
III
d3-Testosterone (d3-T) Sigma-Aldrich, Steinheim, Germany II
Trans-androsterone (3β-AN) Sigma-Aldrich, St. Louis, MO, USA III
Stock  solutions  of  the  standards  (1  mg  mL-1,  5  mM  or  1  mM)  were  pre-
pared  in  MeOH  or  in  ACN  depending  on  the  solubility  of  the  compound.
Further dilutions of the stock solutions were made by using different solvents
depending on the final use of the solution. More detailed information can be
found in studies I-IV.
The samples used in this study are listed in Table 5. Detailed information
about the samples can be found in publications I, II, and IV.
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Table 5. Samples and sample matrix used in the study.
Sample/Matrix Manufacturer/Supplier Publi-cation
Mouse plasma samples University of Turku, CentralAnimal Laboratory, Turku, Finland II
Pooled drug-free
human urine
United Medix Laboratories Ltd.,
Helsinki, Finland I
Artificial plasma
matrix: Ringer’s
solution + 4% (w/v) BSA
University of Helsinki, Faculty of
Pharmacy, Division of
Pharmaceutical Chemistry,
Helsinki, Finland
II
WT SH-SY5Y human
neuroblastoma cell line
samples
University of Helsinki, Faculty of
Pharmacy, Division of
Pharmacology and Toxicology,
Helsinki, Finland
IV
A30P and A53T α-syn
cell line samples
University of Helsinki, Faculty of
Pharmacy, Division of
Pharmacology and Toxicology,
Helsinki, Finland
IV
Mouse brain samples
University of Helsinki, Faculty of
Pharmacy, Division of
Pharmacology and Toxicology,
Helsinki, Finland
IV
3.2 SAMPLES AND SAMPLE PRETREATMENT
PROCEDURES
Several  different biological  sample types were used in this  study in order to
prove the utility of the developed methods for lipid analysis. The samples
were provided as collected, and therefore sample pretreatment procedures
were used as well.
3.2.1 URINE SAMPLES
Pooled drug-free human urine was used to test the feasibility of the new
capLC-µAPPI-MS/MS method for the analysis of anabolic steroids in human
urine samples (I). A 2.5 mL aliquot of pooled drug-free human urine sample
was spiked to a concentration of  100 ng mL-1 MTS (internal  standard).  The
urine was then buffered to pH 5.0 with 0.2 M potassium acetate buffer  and
enzymatically hydrolyzed by 50 mL of β-glucuronidase at 55 ºC for 2 h. 250
mg  of  a  solid  mixture  of  sodium  hydrogen  carbonate  and  potassium  car-
bonate  (2:1,  w/w)  was  added  and  the  samples  were  extracted  using  diethyl
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ether. After centrifugation, the organic layer was separated and evaporated to
dryness.  Finally,  the  samples  were  dissolved  in  100  µL  of  15%  MeOH  and
analyzed by capLC-µAPPI-MS/MS.
3.2.2 MOUSE PLASMA SAMPLES
Mouse plasma samples were analysed by the HPLC-Chip/MS system in order
to prove the feasibility  of  a  newly developed method in the analysis  of  non-
derivatized  steroids  (II).  The  samples  were  obtained  from  mice  with  a
C57B1/129 hybrid background. All animal handling was conducted in ac-
cordance  with  the  Finnish  Animal  Ethics  Committee  and  the  Institutional
animal care policies of the University of Turku, which fulfill the requirements
of the NIH Guide on animal experimentation.
Steroids were extracted from the mouse plasma samples using LLE with
MTBE. Briefly, the procedure was as follows: 1 mL of MTBE was added to a
150  µL  aliquot  of  mouse  plasma.  The  sample  was  vortex  mixed  for  one  mi-
nute and centrifuged (at 2000 rpm for 5 min). The MTBE phase was filtered
into  a  sample  vial  through  a  0.2  µm syringe  filter  (Millipore,  Bedford,  MA,
USA) and evaporated to dryness.  Finally,  the samples were reconstituted in
50 µL of 5% NH4Ac (50 mM, pH 4.5 with acetic acid):MeOH:ACN (1:3:6, v/v)
and vortex mixed just before analysis by the HPLC-Chip/MS system.
3.2.3 MOUSE BRAIN SAMPLES
Three month old male NMRI-mice were used for the analysis of oxysterols
and  vitamin  D metabolites  in  brain  samples  by  UHPLC-APPI-MS (IV).  The
protocol for animal handling was accepted by the Animal Experiments Board
of Finland and experiments were performed according to Finnish legislation.
The mice were anaesthetized using sodium pentobarbital (100 mg kg-1,
i.p.) as the agent and transcardially perfused with phosphate buffered saline
(PBS) for four minutes to purge all the blood out of the brain. Afterwards the
brains were removed from the scull,  frozen on dry ice and stored at  -80 ºC
until assayed.
The intact mice brains were weighed and cut into four parts. A 2.5 µL ali-
quot of a 1 µg mL-1 standard working solution containing the internal stand-
ards  d3-D3 and  d6-27-OH-Chl was added to each brain part. The samples
were homogenized and extracted by LLE. The procedure was as follows: 0.5
mL of a DCM:MeOH mixture (1:1, v/v) was added to the samples, which were
homogenized using ultrasonication with a Branson Sonifier 450 (Branson
Ultrasonics  Corporation,  Danbury,  CT,  USA)  in  an  ice  bath  for  1  min.  The
ultrasonication had an amplitude and efficiency of 90% and 2, respectively.
The  samples  were  centrifuged  (at  13200  rpm  for  5  min),  the  supernatants
were removed and the procedure was repeated. After the second extraction
process, the four supernatants that originated from each intact mouse brain
were  combined  into  one  sample  for  that  respective  brain,  which  was  then
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evaporated to dryness. The samples were reconstituted in 100 µL of MeOH,
centrifuged (at 13200 rpm for 5 min) and the supernatants were moved to a
vial with a glass insert right before analysis by UHPLC-APPI-MS.
3.2.4 CELL LINE SAMPLES
The wild type (WT) SH-SY5Y human neuroblastoma cell line was purchased
from ATCC (LGC Standards, Product # CRL-2266, Middlesex, UK) and cul-
tured as described by Myöhänen et al. 175 Stable cell lines that express A30P
and  A53T  α-syn  were  generated  using  a  lentiviral  vector  as  described  by
Gerard et al.,176 and the transfected cells were cultured as described by
Myöhänen et al.175
The cell lines for the analysis by UHPLC-APPI-MS (IV) were used at pas-
sages  3  to  15  and  grown at  37  ºC  and  5% CO2 in  a  humidified  atmosphere.
For oxidative stress, 1 × 106 cells  were  seeded  in  T25-flasks  and  allowed to
grow overnight. Thereafter, the aggregation process of α-syn was induced by
adding  100  µM  H2O2 and  10  mM  FeCl2 in  cell  culturing  medium  for  three
days as previously described.175,176 All cells (non-stressed and stressed) were
homogenized as described by Myöhänen et al. using 0.1  M Na-K phosphate
buffer (pH 7.0).175 The homogenates were centrifuged (at 16000 g,  4  ºC for
20 min), and thereafter the supernatants and pellets were separated and
stored at -80 ºC until assayed.
A 10 µL aliquot of the 1 µg mL-1 standard working solution that contained
the internal standards d3-D3 and d6-27-OH-Chl was added to the cell pellet.
The  samples  were  homogenized  and  extracted  by  LLE  with  0.5  mL  of  a
DCM:MeOH mixture (2:1, v/v) following the same procedure as was used for
the  brain  samples.  Finally,  the  supernatants  were  combined,  evaporated  to
dryness  and  reconstituted  in  100  µL  of  MeOH  before  analysis  by  UHPLC-
APPI-MS.
3.3 DERIVATIZATION OF STEROIDS
Steroids are relatively nonpolar compounds and therefore not very well ion-
izable by ESI.  Therefore,  it  is  quite common to derivatize these compounds
before analysis in order to enhance the ionization efficiency and thereby the
sensitivity of the method. In this study two different derivatization methods
were used (II and III), but the purposes were quite different. In publication
II, derivatization was used in order to enhance the ionization efficiency in
ESI. In publication III, on the other hand, derivatization was used in order to
increase the difference of either the strength of the ion/molecule interactions
with the drift gas and/or the difference in collision cross sections of the ana-
lytes.  The  purpose  of  this  was  to  improve  the  separation  efficiency  of  the
steroid isomers in the IMS-MS experiments.
33
3.3.1 OXIME DERIVATIZATION
Oxime derivatization was used in publication II in order to enhance the ioni-
zation efficiency in ESI when comparing a commercially available HPLC-
Chip/ESI/MS system to a conventional LC-ESI/MS. An example of the deri-
vatization reaction is shown in Figure 5.
The ketosteroids in the samples were derivatized by adding 600 µL of hy-
droxylamine solution (NH2OH, 100 mM in 50% MeOH) to each sample and
heating at 60 ºC for 30 min in a ULE500 laboratory oven (Memmert, Schwa-
bach, Germany). Thereafter, the samples were analysed.
Figure 5 Example of the oxime derivatization reaction for DHT.
3.3.2 P-TOLUENESULFONYL ISOCYANATE DERIVATIZATION
In  publication  III  steroid  isomers  were  subjected  to  derivatization  by p-tol-
uenesulfonyl  isocyanate  (PTSI).  Figure  6  shows  an  example  of  the  derivati-
zation reaction. In this case, the derivatization was not related to enhancing
the ionization efficiency. The purpose was instead to increase the difference
of  either  the  strength  of  the  ion/molecule  interactions  with  the  drift  gas
and/or the difference in collision cross sections and thus to improve the sep-
aration efficiency of the steroid isomers in the TWIM-MS analysis.
In order to derivatize the samples,  100 µL of  the working standard solu-
tion  of  each  analyte  was  transferred  to  a  glass  vial,  and  the  solution  was
evaporated to dryness. 100 µL of ACN and 20 µL of PTSI (1:10, v/v in ACN)
were added to the vial. The sample mixture was vortexed at ambient temper-
ature for 2 min and the derivatization reaction was stopped by adding 20 µL
of H2O and vortexing for 30 s.  After  this,  860 µL of  MeOH, including 0.1%
NH4OH, was added to the solution.
Figure 6 Example of the p-toluenesulfonyl isocyanate derivatization reaction.
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The derivatization of the hydroxyl group at position C17 of α-ES was con-
firmed  by  nuclear  magnetic  resonance  (NMR)  using 1H, 13C, COSY, HSQC
and  HMBC  NMR  analysis.  A  chemical  synthesis  was  performed  in  larger
scale before the actual analysis step in order to achieve the amount of prod-
uct  needed  for  NMR  analysis.  More  detailed  information  can  be  found  in
Electronic Supplementary Information 1 in publication III.
3.4 INSTRUMENTATION AND ANALYTICAL METHODS
The analyses were performed on several different mass spectrometers with
variable additional instruments. New analytical methods were developed
with the purpose of assessing novel methods for the analysis of the selected
lipids.  Table 6 briefly  outlines the instrumentation used in this  study.  More
detailed information can be found in studies I-IV.
The home-built mass spectrometer ion source, µAPPI, used in publication
I for analyzing anabolic steroids in urine samples, was originally described in
2004 by Kauppila et al.142 Since that first introduction, some improvements
have been implemented, but the basic functions remain the same. A sche-
matic view of the µAPPI setup is presented in Figure 7. The fabrication of the
microchips  used  for  the  ionization  has  been  presented  in  more  detail  by
Saarela et al.144 Publication I  also contain detailed descriptions on the posi-
tioning of the microchip in front of the mass spectrometer.
Figure 7 Schematic view of the µAPPI setup in front of the mass spectrometer
Tables 7-10 briefly summarize the analytical methods used and developed
in this study. Detailed information can be found in studies I-IV.
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Table 6. Instrumentation used in this study.
Instrument Manufacturer Note Publi-cation
PE Sciex API 300
triple quadrupole
MDS Sciex, Concord,
Canada
A xyz positioning stage was used for positioning the microchip
in front of the mass spectrometer I
75-72 nitrogen
generator
Whatman Inc., Haverhill,
MA, USA
Used for generating purified nitrogen to be used as a curtain
and nebulizer gas I
Krypton discharge
UV lamp (PKS 100) Cathodeon, Cambridge, UK
Used for the photoionization of the analytes using 10 eV photon
energy I
APPI power source University of Groningen,Groningen, The Netherlands
Custom-made at the Electronics Facility and Mechanical
Workshop I
dc power supply
(IPS-603) RS Components, Corby, UK
Used for heating of the microchip at 3.5 W of power
(corresponding to approximately 350 ºC) I
Mass flow
controller (GCF17)
Aalborg, Orangeburg, NY,
USA
Used for regulating the nebulizing gas flow (150 mL min-1) into
the microchip I
Syringe pump
(PHD 2000)
Harvard Apparatus,
Holliston, MA, USA
Used for dopant (toluene) delivery at a flow rate of 2 µL min-1
and for the optimization of the mass spectrometer voltages for
each analyte
I
CapLC
(1100 series)
Agilent Technologies,
Waldbronn, Germany
Symmetry Shield column (100 × 0.3 mm i.d., particle size
3.5 µm), Waters, Milford, MA, USA
Only the pump and degasser was used in publications II and IV
I
II, IV
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Table 6 continued Instrumentation used in this study.
Instrument Manufacturer Note Publi-cation
Agilent 6410 triple
quadrupole
Agilent Technologies,
Waldbronn, Germany
The mass spectrometer was used with the HPLC-Chip/MS
interface II
Parker Balston N2-22
nitrogen generator
Parker Hannifin, Haverhill,
MA, USA
Used for generating purified nitrogen to be used as a drying
and collision gas II
Syringe pump
Cole-Parmer, Vermon Hills,
IL, USA
Used for the optimization of the ionization and mass
spectrometric conditions for each analyte when using the chip
cube
II
RRLC (1200 series) Agilent Technologies,Waldbronn, Germany
Zorbax SB-C18 column (50 × 2.1 mm i.d., particle size 1.8 µm),
Agilent Technologies, Waldbronn, Germany II
NanoLC
(1200 series)
Agilent Technologies,
Waldbronn, Germany
The nanopump (and degasser) and the microwell-plate
autosampler were used for sample delivery only. II
Chip cube (HPLC-
Chip/MS interface)
Agilent Technologies, Santa
Clara, CA, USA
The polymeric chip (either HPLC or MS calibration and
diagnostic chip) is inserted into the chip cube, which includes a
miniature camera for spray visualization
II
MS calibration and
diagnostic chip
Agilent Technologies, Santa
Clara, CA, USA
Used for the optimization of ionization and mass spectrometric
conditions for each analyte II
HPLC chip Agilent Technologies, SantaClara, CA, USA
Integrates a 40 nL enrichment column packed with 5 µm
Zorbax 300 SB-C18 particles, a 50 µm (d) × 75 µm (w) × 43
mm (l) RP-LC separation column packed with 5 µm Zorbax
300 SB-C18 particles, and a nanospray emitter (50 µm i.d.)
II
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Table 6 continued Instrumentation used in this study.
Instrument Manufacturer Note Publi-cation
Waters Synapt
HDMS Waters, Manchester, UK
Including a hybrid quadrupole/traveling wave ion
mobility/orthogonal acceleration time-of-flight geometry III
Waters ACQUITY
UPLC® I Class Waters, Milford, MA, USA
ACQUITY UPLC® BEH C18 column (100 × 2.1 mm i.d.,
particle size 1.7 µm), Waters, Milford, MA, USA IV
Waters ACQUITY
UPLC® Waters, Milford, MA, USA
ACQUITY UPLC® HSS C18 column (100 × 2.1 mm i.d.,
particle size 1.8 µm IV
Waters Synapt
G2-S HDMS
(Q-TOF)
Waters, Wilmslow, UK
Interfaced with a ZsprayTM Atmospheric Pressure
Photoionization/Atmospheric Pressure Chemical Ionization
(APPI/APCI) dual source, Waters, Milford, MA, USA
IV
Waters® XevoTM
TQ-S MS
(triple quadrupole)
Waters, Milford, MA, USA
Interfaced with a ZsprayTM Atmospheric Pressure
Photoionization/Atmospheric Pressure Chemical Ionization
(APPI/APCI) dual source, Waters, Milford, MA, USA
IV
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Table 7. Analytical methods used and developed for the analysis of anabolic steroids in human urine samples by capLC-µAPPI-MS/MS (I).
Analytes
Molecular
weight
Mass spectrometric
conditions
Chromatographic conditions
Mobile phase Gradient
Positive ion mode
µAPPI
Selected reaction
monitoring (SRM)
A: H2O:MeOH
(95:5, v/v)
B: MeOH
Time (min) Org %
Injection volume:
3 µL
Flow rate:
6 µL min-1
17MDN 300
0-2 15-75
MTS 302 2-13 75-95
13-15 95-100
NAN 274 15-30 100
30-30.5 100-15
NANm 276 30.5-60.5 15
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Table 8. Analytical methods used and developed for the analysis of oxime derivatized and non-derivatized steroids by the conventional LC-MS system and
by the HPLC-Chip/MS system (II).
Analytes Molecularweight
Mass spectrometric
conditions Chromatographic conditions
Oxime deriv. Conventional LC-MS system
Positive ion mode
ESI
SRM
Mobile phase
A: H2O + 0.025%
(v/v) HCOOH
B: MeOH + 0.025%
(v/v) HCOOH
Gradient
Injection volume:
40 µL
Flow rate:
0.2 mL min-1
AN 286 Time (min) Org %
AND 290 0-0.7 60
0.7-5 60-90
DHEA 288 5-5.4 90
5.4-5.41 90-60
DHT 290 5.41-7 60
ES 270 HPLC-Chip/MS system
Gradient Sample loading:
3% B, flow rate
4 µL min-1
Injection volume:
0.5 µL
Flow rate:
0.3 µL min-1
17-OH-PREG 332 Time (min) Org %
PREG 316 0-0.3 5-50
0.3-7 50-85
17-OH-PROG 330 7-7.1 85-5
7.1-20 5
T   288
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Table 8 continued Analytical methods used and developed for the analysis of oxime derivatized and non-derivatized steroids by the conventional LC-
MS system and by the HPLC-Chip/MS system (II).
Analytes Molecularweight
Mass spectrometric
conditions Chromatographic conditions
Non-deriv. HPLC-Chip/MS system
Positive ion mode
ESI
SRM
Mobile phase
A: NH4Ac
(50 mM, pH 4.5):H2O
(1:9, v/v)
B: NH4Ac
(50 mM, pH 4.5)
MeOH:ACN
(1:3:6, v/v/v)
Gradient
Sample loading:
3% B, flow rate
4 µL min-1
Injection volume:
0.75 µL
Flow rate:
0.3 µL min-1
A 360
AN 286
Time (min) Org %
CORT 346
0-0.3 5-40
CS 360 0.3-3.9 40-40.2
3.9-4 40.2-76
11-DC 346 4-6.6 76-80
6.6-7.8 80-100
HC 362 7.8-7.9 100-5
7.9-32.9 5
PROG 314
T 288
41
Table 9. Analytical methods used and developed for the separation of steroid isomers by TWIM-MS (III).
Analytes Molecularweight
MS
conditions
TWIM-MS conditions
Non-derivatized analytes Derivatized analytes
Direct
infusion:
Concentration:
10 µg mL-1
Flow rate:
30 µL min-1
MS scan
Sample
solvent
Ion
mode
ESI+
ESI-
ESI+
Drift gas
pressures Sample solvent:
MeOH + 0.1% NH4OH
Ion mode:
ESI-
Drift gas pressures:
N2: 2.0 mbar, 2.5 mbar, 3.0 mbar
CO2: 1.0 mbar, 1.3 mbar
N2: 2.0 mbar
CO2: 1.0 mbar
N2: 2.0 mbar
CO2: 1.3 mbar
N2: 2.0 mbar
CO2: 1.3 mbar
3α-AN 290 MeOH +
0.1% HCOOH
MeOH +
0.1% NH4OH
3β-AN 290
α-ES 272
β-ES 272
MeOH +
0.1% HCOOH
17α-T 288
17β-T 288
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Table 10. Analytical methods used and developed for the analysis of vitamin D related compounds and oxysterols in brain samples and in cell line samples
by UHPLC-APPI-MS (IV).
Analytes Molecularweight
MS
conditions
Chromatographic conditions
Mobile phase Gradient
Positive ion
mode
APPI
SRM (TQ-S)
Sensitivity mode
& MSe-mode
(Q-TOF)
A: H2O
B: MeOH
Time (min) Org %
Injection volume:
5 µL (TQ-S)
7.5 µL (Q-TOF)
Flow rate:
0.3 mL min-1
Dopant (TQ-S):
toluene
flow rate 20 µL min-1
Lock mass and dopant
(Q-TOF):
0.1 µg mL-1 PROG in toluene
flow rate 30 µL min-1
D3 384
d3-D3 387 0-14 80-100
D2 396 14-17 100
1α,25-OH-D3 416
25-OH-D3 400 Column wash:
5 min
10% DCM in MeOH
d6-27-OH-Chl 408
27-OH-Chl 402
24-OH-Chl 402
22-OH-Chl 402 Column re-equilibration:
7α-OH-Chl 402 6 min
7β-OH-Chl 402 80% B
DESMO 384
7-OXO 400
7-DHYD 384
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4 RESULTS AND DISCUSSION
The need for new fast, robust and highly sensitive methods in lipid analysis is
continuously growing. The variety of compounds of interest is also increasing
constantly. In this study new methods for lipid analysis were developed and
the feasibilities of these methods were tested in the analyses of several bio-
logical samples. This section of the thesis summarizes the main results of the
work. More details regarding the results can be found in the original publica-
tions (I-IV).
4.1 CAPLC/MICROCHIP-APPI/MS/MS IN THE ANALYSES
OF ANABOLIC STEROIDS OF URINE SAMPLES
The aim of the first part of this study was to develop a capLC-µAPPI-MS/MS
method for the analysis of anabolic steroids in human urine samples. For this
purpose, an in-house built microchip was used. This heated nebulizer micro-
chip had hitherto been used for several applications, but no LC based meth-
ods for biological samples had been developed. Nevertheless, the technique
of  µAPPI  seemed  promising  for  this  purpose  since  it  would  allow  smaller
consumption of organic solvents and it would also provide the possibility of
lower flow rates. The possible use of lower flow rates, on the other hand, al-
lowed  the  combination  of  a  capLC  to  the  mass  spectrometer,  which  under
normal conditions is not possible with commercial APPI sources, since these
usually  require flow rates in the order of  200 µL min-1 for appropriate ioni-
zation.  The  use  of  the  heated  nebulizer  microchip  at  lower  flow  rates  also
produces a narrower gas jet, which provides high ion transfer into the mass
spectrometer and therefore enhances the sensitivity of the method.
The positioning of the heated nebulizer microchip, the nebulizing gas (N2)
flow rate, the dopant (toluene) flow rate, and the heating power of the micro-
chip significantly affected the signal intensity and stability. Therefore, careful
positioning of the microchip and optimization of the aforementioned param-
eters were necessary. The APPI mass spectra of the analytes (17MDN, MTS,
NAN and NANm) were acquired and the protonated molecule ([M + H]+) of
each analyte was chosen to be the precursor ion in the following SRM anal-
yses. The collision energy (CE) was separately optimized for each analyte and
MS/MS spectra were acquired. The most abundant and selective product
ions were chosen for the SRM analyses.
The product ion chromatograms of the analytes in the spiked urine sam-
ples  showed  good  chromatographic  behaviour  (Figure  8).  All  compounds
were separated to baseline with repeatabilities of the retention times (%RSD
tR) below 0.9% (Table 11). The peak half-widths (Wh) and asymmetry factors
(As) were 0.09-0.12 min and 1.04-1.67, respectively (Table 11). These results
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indicate  that  the  possible  dead  volume  of  the  vaporizer  channel  in  the  mi-
crochip causes no peak broadening and that the microchip is suitable for this
type of analyses. The lack of peak broadening also shows, that the tempera-
ture  of  the  microchip  was  high  enough  to  avoid  adsorption  of  the  analytes
onto the surface of  the microchip channel.  Analyses of  blank urine samples
showed, that the chemical and biological background caused no interference
in the analysis  and no memory effect  was observed after  the analysis  of  the
spiked urine sample (Figure 8).
Figure 8 SRM chromatograms of the analytes obtained from spiked urine (50 ng mL-1) and
blank urine samples.
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Table 11. Retention times (tR), repeatability of retention times (%RSD), peak widths at half-
height (Wh), peak base width (Wb), and peak asymmetry (As). The concentration of the injected
sample was 250 ng mL-1, and the injection volume was 3 µL.
Analyte tR(min)
%RSD tR
(N = 6)
Wh
(min)
Wb
(min) As
17MDN 10.62 0.4 0.111 0.323 1.04
MTS 10.58 0.4 0.115 0.340 1.67
NAN 9.87 0.9 0.092 0.221 1.07
NANm 11.01 0.3 0.101 0.255 1.40
The  developed  method  was  evaluated  with  respect  to  linearity,  limit  of
detection (LOD) and repeatability of injection. Full validation of the quanti-
tative performance of this method was not carried out, because quantitative
analysis  is  seldom  necessary  in  doping  analysis.  In  order  to  determine  the
linearities  and  LODs,  the  urine  samples  were  spiked  with  the  selected  ana-
lytes to concentrations of 0.1, 0.5, 1, 2.5, 5, 7.5, 10, 25, 50, 100, 250 and 500
ng mL-1, and pretreated as described in section 3.2.1. Calibration curves were
obtained  from  the  analyte  to  internal  standard  (MTS)  peak  area  ratios  by
using linear regression with 1/x weighting. The coefficients of determination
(R2) were between 0.995 and 0.999, and the method was linear up to 500 ng
mL-1 (17MDN and NANm) or up to 250 ng mL-1 (NAN) thus indicating ade-
quate linearity of the method (Table 12). The LODs (at S/N = 3) were below
15 ng mL-1 for all of the compounds, which indicated reasonable sensitivity of
the method. The reasonable sensitivity can be stated since the general mini-
mum required performance level by the world anti-doping agency for exoge-
nous anabolic  androgenic steroids is  5  ng mL-1 and here two out of  three of
the measured compounds show LODs below this limit.
One  urine  sample  was  spiked  to  a  concentration  of  250  ng  mL-1, pre-
treated as described in section 3.2.1, and analyzed as six replicates in order to
evaluate the repeatability of injection. The %RSDs of the peak areas were
below  10%  for  all  of  the  compounds,  which  indicated  good  repeatability  of
the method.
The results showed good quantitative behaviour of the developed method
and that the method could be applicable for doping analysis, where quantita-
tive analysis is seldom required. Nevertheless, more precise validation re-
garding the repeatability of the method at lower concentrations and optimi-
zation of the total analysis time should be conducted before implementation
of the method in a routine laboratory.
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Table 12. Linear ranges, coefficients of determination (R2), limits of detection (LODs), and
repeatability of injection (%RSD).
Analyte R
2
(no. of points, range (ng mL-1))
LOD
(ng mL-1) %RSD
17MDN 0.9990 0.5 9.3
(10, 1-500)
NAN 0.9954 0.3 4.2
(9, 1-250)
NANm 0.9964 15 8.8
(5, 25-500)
4.2 COMPARISON BETWEEN THE HPLC-CHIP/ESI/MS
AND CONVENTIONAL LC/ESI/MS, AND ANALYSIS
OF STEROIDS OF PLASMA SAMPLES BY THE
HPLC-CHIP/ESI/MS
There  are  only  a  couple  of  commercial  microchip  based  LC-MS  systems
available today. The feasibility of a commercial microchip based HPLC-
Chip/MS  system  in  the  analysis  of  steroids  was  studied  as  one  part  of  this
study. The HPLC-Chip integrates a sample-enrichment column, a reversed
phase LC separation column, and a nanoESI on a single polyimide chip. This
system was used for the analysis of eight non-derivatized steroids in mouse
plasma samples and the system was also compared to a conventional narrow-
bore LC-MS system using oxime-derivatized steroids.
4.2.1 A COMPARISON BETWEEN THE HPLC-CHIP/MS SYSTEM AND
THE CONVENTIONAL LC-ESI/MS SYSTEM
Oxime derivatives of ketosteroids were used in the comparison of the stand-
ard LC-MS with the HPLC-Chip/MS system. Oxime derivatization was cho-
sen in order to enhance the ionization efficiency of the non-polar steroids in
ESI and thus to enhance the sensitivity of the newly developed method. The
ionization parameters were optimized for each analyte separately and MS
spectra  were  acquired.  All  compounds  showed  abundant  protonated  mole-
cules. These were chosen to be the precursor ions for the following SRM ex-
periments, and MS/MS spectra were acquired. Product ions for the SRM ex-
periments were chosen from the MS/MS spectra based on maximal sensitiv-
ity and selectivity and compound-specific SRM parameters were optimized.
The  chromatographic  performance  of  the  conventional  LC-ESI/MS  was
clearly better than the HPLC-Chip/MS system (Figure 9). The peaks were
narrower (Wb =  0.22-0.38  min  compared  to  Wb =  0.57-0.84  min)  and  the
resolution  was  better  for  the  LC-ESI/MS.  The  reason  for  this  was  probably
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due to differences in column properties. The particle size in the conventional
column was much smaller (1.8 µm) than in the chip column (5 µm). The pore
size in the conventional column was also much smaller (80 Å against 300 Å
in the chip column). Even though the resolution was poorer with the HPLC-
Chip than with the conventional column, the co-eluting compounds could be
separated using MS/MS. In many cases,  however,  isomeric steroids can not
be  separated  by  MS/MS  and  the  separation  relies  on  the  chromatographic
resolution. In these cases, the performance of the HPLC-Chip/MS system
with  5  µm  particles  may  not  be  sufficient  to  separate  isomeric  steroids  in
authentic biological samples. Another drawback of the HPLC-Chip is its nar-
row column (50 µm × 75 µm), since this limits the mass loading capability of
the  chip.  The  mass  loading  capability  of  the  HPLC-Chip  was  tested  by  in-
jecting 1.0 µL and 0.5 µL of a 15 nM standard sample. The results show, that
an injection volume of 1.0 µL causes severe peak broadening compared to an
injection  volume  of  0.5  µL  (Figure  9A  and  B).  With  the  conventional  LC-
ESI/MS, on the other hand, an injection volume of 40 µL could be used with-
out causing peak broadening (Figure 9C).
Besides the chromatographic performance, the quantitative performances
of the two systems were also compared. LODs, linearities and repeatabilities
were  evaluated  using  standard  samples  (Table  13).  The  LODs,  when  pre-
sented as concentrations, were found to be slightly higher for the HPLC-
Chip/MS system (50-300 pM) than for the conventional LC-ESI/MS system
(10-150  pM).  However,  when the  LODs are  expressed  as  injected  amounts,
the sensitivity of the HPLC-Chip/MS system, which used an injection volume
of 0.5 µL was approximately 50 times higher compared to the conventional
LC-ESI/MS system, which used an injection volume of 40 µL. The result is in
agreement with the assumption that ESI/MS behaves more like a concentra-
tion-sensitive detector than a mass-flow sensitive detector, even if the mass
spectrometer generally is a mass-flow sensitive detector. This can be ex-
plained by the fact, that the expected decrease in signal intensity due to de-
creased  mass  flow at  lower  flow rates  is  compensated  by  more  efficient  ion
production.177 This  is  because  the  initial  charged  droplet  diameter  de-
creases178 and droplet charging becomes more efficient179 with decreasing
flow  rates.  This  in  turn  leads  to  more  efficient  droplet  disintegration  and
therefore to more efficient ion production at low flow rates.180 The practical
consequence is that the use of the HPLC-Chip/MS system is clearly advanta-
geous in the analysis of low-volume samples.
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Figure 9 SRM chromatograms of the oxime derivatized steroids in standard samples (15
nM). (A) Injection volume of 1 µL with the HPLC-Chip/MS system, (B) injection volume of 0.5 µL
with the HPLC-Chip/MS system and (C) injection volume of 40 µL with the conventional LC-
ESI/MS system.
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Table 13. Limits of detection (LODs), coefficients of determination (R2), repeatability of retention times (%RSD tR), repeatability of peak areas (%RSD A),
and carry-over of the HPLC-Chip/MS system for the oxime-derivatized steroids. The sample volumes injected were 40 µL in the conventional LC-ESI/MS system
and 0.5 µL in the HPLC-Chip/MS system.
Analyte
LOD pM (pg mL-1),
S/N > 3
R2,
range 0.075-180 nM %RSD tR (N = 5) %RSD A (N = 5)
Carry-over of
HPLC-
Chip/MS
system (%)
LC-
ESI/MS
HPLC-
Chip/MS
LC-
ESI/MS
HPLC-
Chip/MS
LC-
ESI/MS
HPLC-
Chip/MS
LC-
ESI/MS
HPLC-
Chip/MS
AN 30 (9) 50 (17) 0.9934 0.9993 0.5 0.1 6.1 2.7 4.1
AND 50 (15) 100 (29) 0.9970 0.9953 0.1 0.0 10.5 10.8 3.3
DHEA 75 (21) 100 (29) 0.9967 0.9979 0.5 0.1 9.1 2.4 3.5
DHT 150 (44) 300 (87) 0.9987 0.9975 0.4 0.2 6.8 3.5 5.2
ES 75 (20) 100 (27) 0.9969 0.9961 1.0 0.3 5.9 7.9 3.4
PREG 30 (10) 50 (16) 0.9944 0.9946 0.1 0.1 8.6 7.3 14.2
17-OH-
PREG 75 (25) 100 (33) 0.9975 0.9981 0.7 0.0 7.0 5.9 3.4
17-OH-
PROG 75 (25) 75 (25) 0.9956 0.9990 0.5 0.1 6.9 4.2 2.9
T 10 (3) 50 (14) 0.9961 0.9990 0.3 0.1 5.3 1.8 3.8
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The coefficients of determination (R2) were calculated using linear regres-
sion  with  1/x  weighting  (Table  13).  The  results  (0.993-0.999)  were  deter-
mined within a concentration range of 0.075-180 nM using 7-11 data points
depending  on  the  analyte.  It  can  be  seen,  that  based  on  the  results  both
methods are linear within the application range and that  they do not mark-
edly differ from each other. The injection repeatability was also studied and
compared between both systems. Five replicate injections were made using a
15 nM standard sample, and %RSDs were calculated for the retention times
and  for  the  peak  areas  (Table  13).  The  results  show  that  %RSDs  are  below
1.0% for the retention times and below 11% for the peak areas. Additionally,
the accuracies were well within the general range of 80-120%. These results
indicate  good  chromatographic  and  quantitative  repeatabilities  and  good
accuracies of the methods.
Carry-over  of  the  HPLC-Chip/MS  system  was  tested  in  addition  to  the
evaluation of the aforementioned general qualification parameters. This was
done by injecting a reagent blank sample immediately after the analysis of a
15 nM standard sample. Peak areas from the standard and the blank samples
were  compared  and  a  significant  carry-over,  typically  between  2%  and  5%,
was detected (Table 13). This seemed to result from the built-in six-way mi-
crovalve of the microchip, and the problem was avoided by flushing the mi-
crovalve  with  a  few reagent  blank  injections  prior  to  the  next  sample  injec-
tion. The conventional LC-ESI/MS, on the other hand, showed no carry-over.
4.2.2 THE FEASIBILITY OF THE HPLC-CHIP/MS SYSTEM FOR THE
ANALYSIS OF NON-DERIVATIZED STEROIDS
Derivatization (e.g. oxime-derivatization) of steroids cannot be used for the
development  of  a  universal  analysis  method  suitable  for  all  steroids,  since
most of the existing derivatization procedures can only occur for steroids that
possess a specific functional group.64,117,181 The analysis of non-derivatized
steroids,  on  the  other  hand,  seldom  provides  the  sensitivity  needed  for  the
analysis of actual biological samples. Nevertheless, the HPLC-Chip/MS sys-
tem provides improved sensitivity when presented as injected amounts over
the conventional LC-ESI/MS system and therefore the testing of this system
with non-derivatized steroids was meaningful.
After  optimizing  the  instrument  parameters,  MS  and  MS/MS  spectra  of
the non-derivatized steroids were acquired. All steroids produced an abun-
dant  protonated  molecule  and  a  less  abundant  sodium  adduct  ion  with
minimal or no fragmentation. Product ions were chosen for SRM analyses in
order to achieve maximum sensitivity and specificity and the compound spe-
cific SRM parameters were optimized.
The chromatographic performance of the HPLC-Chip/MS system for the
non-derivatized steroids (Figure 10) was comparable to that for the derivat-
ized steroids (Figure 9B).  The peak widths (Wb) were 0.213-0.576 min, and
no  significant  peak  tailing  was  observed.  The  resolution  was  again  insuffi-
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cient to separate all the steroids, but the co-eluting compounds could be sep-
arated by MS/MS. These results, and the fact that no significant peak tailing
can  be  observed,  indicate  reasonable  chromatographic  performance  of  the
method with respect to the separation of the analytes.
Figure 10 SRM chromatograms of the non-derivatized steroids in standard samples (7.5 ng
mL-1) using the HPLC-Chip/MS system. The injection volume was 0.75 µL.
The quantitative performance of the HPLC-Chip/MS system for the non-
derivatized steroids was evaluated with respect to LODs, linearity, and re-
peatability using a spiked BSA-based artificial plasma matrix (Table 14). The
LODs (S/N ≥ 3) ranged from 0.3 nM to 2.2 nM (0.1-0.8 ng mL-1), which were
about five to seven times higher than those determined for the oxime-deri-
vatized steroids (Table 13). The higher sensitivity obtained for the derivatized
steroids originates from the basic character of the oxime group, which signifi-
cantly improves the ionization efficiency in ESI.182 Calibration curves were
measured  at  a  concentration  range  of  0.075-100  ng  mL-1 using 6-12 data
points, depending on the analyte. The coefficients of determination (R2) us-
ing  linear  regression  with  1/x  weighting  were  typically  better  than  0.990,
which  indicates  acceptable  linearity  of  a  method  developed  based  on  new
technology. The repeatability of injection was evaluated by injecting six repli-
cates of  a  25 ng mL-1 standard sample.  The %RSDs were found to be below
0.5% and below 10% for the retention times and the peak areas, respectively.
This indicates good repeatability  of  the method.  The accuracies were within
the general range of 80-120% indicating good accuracy of the method.
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Table 14. Limits of detection (LODs), coefficients of determination (R2), repeatability of
retention times (%RSD tR) and repeatability of peak areas (%RSD A) for the non-derivatized
steroids with the HPLC-Chip/MS system. The sample volume injected was 0.75 µL.
Analyte
LOD
nM (ng mL-1)
S/N ≥ 3
R2,
range 0.075-100
ng mL-1
%RSD tR
(N = 6)
%RSD A
(N = 6)
A 2.2 (0.8) 0.9878 0.5 9.2
AN 1.8 (0.5) 0.9964 0.3 4.6
CORT 0.7 (0.2) 0.9943 0.3 5.7
CS 0.3 (0.1) 0.9911 0.3 5.0
11-DC 0.3 (0.1) 0.9846 0.3 5.0
HC 0.7 (0.3) 0.9900 0.2 3.2
PROG 1.6 (0.5) 0.9750 0.1 6.5
T 1.7 (0.5) 0.9921 0.2 3.0
The  feasibility  of  the  HPLC-Chip/MS  system  was  demonstrated  in  the
analysis of non-derivatized steroids in eight female and seven male mouse
plasma samples (Table 15). Of the eight steroids measured, only CORT could
be  detected  in  all  of  the  samples  at  concentrations  that  ranged  from  7.3  to
259  nM.  The  CORT  concentrations  in  females  were  approximately  six-fold
(168 ± 64.1 nM) that of males (34.5 ± 11.1 nM). This result is in line with re-
cent research results.183 Various  androgens  were  detected  in  some  of  the
samples taken from males, but not in any of the samples from females. This
difference  results  from  the  high  variation  in  androgen  concentrations  in
mouse plasma, as well as from their low concentrations in females. The rest
of the analyzed steroids could not be detected in any of the samples.
In  conclusion,  the  developed  methods  show  acceptable  quantitative  be-
haviour for both oxime derivatized and non-derivatized steroids. The HPLC-
Chip/MS system appears to be advantageous for low volume samples and it
is  feasible for the analysis  of  the selected non-derivatized steroids in mouse
plasma samples. The conventional LC-MS system, on the other hand, showed
slightly better sensitivities when expressed as the concentrations of the ana-
lytes present in the samples. Nevertheless, the methods presented here
would need further validation and optimization in order to be able to achieve
the  often  required  pM or  pg  mL-1 sensitivity levels for steroid analysis. The
results shown here suggest that this could possibly be achieved by using deri-
vatization and the most sensitive mass spectrometer combined with the
HPLC-Chip.  Unfortunately this  would limit  the method to steroids having a
specific functional group in their structure.
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Table 15. Quantified amounts of steroids present in mouse plasma samples. LLOQ stands
for “lower limit of detection” and it means that the analyte was detected but due to its low amount
it could not be quantified.
Sample
Steroid, nM (ng mL-1)
CORT A T AN
Females
1 259 (90) < LLOQ - -
2 75 (26) < LLOQ - -
3 73 (25) < LLOQ - -
4 182 (63) < LLOQ - -
5 122 (42) < LLOQ - -
6 124 (43) < LLOQ - -
7 147 (51) < LLOQ - -
8 77 (27) < LLOQ - -
Males
1 37 (13) 7.0 (2.5) < LLOQ -
2 7.3 (2.5) 3.7 (1.3) 24 (6.9) 3.2 (0.9)
3 17 (5.9) - - -
4 23 (8.0) - < LLOQ -
5 11 (3.8) < LLOQ < LLOQ 2.2 (0.6)
6 29 (10) - 61 (18) -
7 32 (11) - - -
4.3 SEPARATION OF STEROID ISOMERS BY ION
MOBILITY MASS SPECTROMETRY
Analysis of steroid isomers by conventional GC-MS and LC-MS techniques is
generally considered time consuming and laborious, since it often requires
very  long  chromatographic  runs  in  order  to  achieve  adequate  separation  of
the  isomers.  Therefore,  the  feasibility  of  ESI-TWIM-MS  in  the  analysis  of
selected non-derivatized and PTSI-derivatized steroid isomers was investi-
gated.  Additionally,  changes  in  the  separation  efficiency  of  the  steroid  iso-
mers  as  a  result  of  using  two  different  drift  gases  (N2 and  CO2) at different
pressures was studied.
Of the non-derivatized steroids, 17α-T and 17β-T were the best ionized in
positive ion mode as [M + H]+, whereas [M + Na]+ dominated the spectra for
3α-AN and 3β-AN. The negative ion mode was more efficient for α-ES, β-ES
and all the PTSI derivatives, thus these analytes were monitored as [M – H]-.
Under  optimized  conditions  the  three  different  steroids  (ES,  AN  and  T)
were  successfully  separated  within  milli-seconds  by  TWIM-MS  (Figure  11).
The α/β steroid isomers, however, could not be separated from each other
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under  any  of  the  applied  drift  gas  conditions.  This  is  probably  due  to  very
similar  collision  cross  sections  of  the  isomers  and  the  similar  strengths  of
their  ion/molecule  interactions  with  the  drift  gas.  This  result  was  slightly
unexpected, since it was assumed, that the more bent ring structure of the β-
isomers (of the aliphatic steroids) would cause a more compact structure and
therefore  display  shorter  drift  times  compared  to  the  α-isomers  with  more
planar ring structures.
Figure 11 Selected ion mobility responses of the native steroid isomers (10 µg mL-1): (A) N2
(2.0 mbar) as the drift gas and (B) CO2 (1.3 mbar for α-ES & β-ES and 17β-T & 17α-T, and 1.0
mbar for 3α-AN & 3β-AN) as the drift gas.
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The  steroid  isomers  could  not  be  separated  in  their  native  forms,  thus
they were PTSI-derivatized in order to increase the difference of either the
strength of their ion/molecule interactions with the drift gas and/or the dif-
ference in shape (i.e. their collision cross section). The derivatization facili-
tated sufficient separation efficiency for the steroid isomers. The TWIM-MS
conditions and the ionization parameters were optimized for each PTSI deri-
vatized  isomer  pair  and  the  separation  efficiency  was  evaluated  in  terms  of
peak-to-peak resolution (Rp-p) under different conditions (Table 16).
Table 16. Peak-to-peak resolution of the TWIM-MS separation of the PTSI-derivatized
steroid isomers.
Isomer pair
CO2 (mbar) N2 (mbar)
1.0 1.3 2.0 2.5 3.0
α-ES & β-ES 0 0.55 0.68 0.77 0.78
3α-AN & 3β-AN 0.90 0.98 0.92 1.08 1.24
17α-T & 17β-T 0.60 0.61 0.74 0.93 0.84
In addition to separation efficiency, the effects of different drift gas con-
ditions on the sensitivity of the analysis were studied. When the pressure of
N2 was  raised  from 2.0  mbar  to  3.0  mbar,  and  that  of  CO2 raised from 1.0
mbar  to  1.3  mbar,  the  Rp-p between the different steroid isomers increased
from 0.68-0.92 to 0.78-1.24 and from 0.00-0.90 to 0.55-0.98, respectively
(Table  16).  This  indicates  that  Rp-p increases  as  the  drift  gas  pressure  is
raised. The sensitivity, however, decreased to about one-tenth when the pres-
sure of N2 was raised from 2.0 mbar to 3.0 mbar and between a half and one-
third  when the  pressure  of  CO2 was  raised  from 1.0  mbar  to  1.3  mbar.  The
best compromise between Rp-p and  sensitivity  based  on  these  results  was
achieved at pressures of 2.5 mbar of N2 or 1.3 mbar CO2.
The comparison between drift gases at optimized pressures show that all
three  pairs  of  α/β isomers  could  be  properly  resolved  (Figure  12).  In  other
words, the Rp-p values when using N2 as the drift gas at a pressure of 2.5 mbar
were 1.08, 0.93, and 0.77 for 3α-AN and 3β-AN, 17β-T and 17α-T, and α-ES
and β-ES, respectively (Table 16). The corresponding values when using CO2
as the drift gas at 1.0 mbar were 0.98, 0.61 and 0.55 (Table 16). These results,
along  with  the  Rp-p values  measured  at  other  pressures  (Table  16),  indicate
that using N2 as the drift gas provides better separation efficiency compared
to CO2 for the PTSI-derivatized steroid isomers.
The  performance  of  the  analysis  method  was  evaluated  using  N2 as  the
drift  gas  at  the  pressure  of  2.5  mbar.  LODs  and  repeatabilities  of  injection
and of the derivatization reaction were determined and are presented in Ta-
ble 17.  The calculated LODs (at  S/N = 3) were below 25 ng mL-1 for  all  iso-
mers, thus indicating reasonable sensitivity of the method. Repeatability of
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injection was determined by five replicate injections of a standard sample at
a concentration of 100 ng mL-1. The results show good quantitative repeata-
bility for all steroid isomers as the %RSDs were below 13%. Repeatability of
the derivatization reaction was measured by injecting four separately pre-
pared  samples  of  the  steroid  isomers  at  a  concentration  of  10  µg  mL-1. The
results show that the derivatization reaction is repeatable for all steroid iso-
mers,  with  %RSDs  below  7%.  Since  the  drift  times  varied  less  than  2%  be-
tween different measurements (N =  5)  it  could  also  be  concluded,  that  the
TWIM-MS method is very robust.
Figure 12 Selected ion mobility responses of the PTSI-derivatized steroid isomers (10 µg mL-
1) using N2 (2.5 mbar) as the drift gas: (A) α-ES & β-ES, (B) 17β-T & 17α-T, and (C) 3α-AN & 3β-
AN.
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Table 17. Limits of detection (LODs), repeatability of injection (%RSD A (injection)),
repeatability of drift times (%RSDdrift-time (injection)), and repeatability of the derivatization reaction
(%RSD A (derivatization)) for the PTSI-derivatized steroid isomers.
Steroid
isomer
LOD
(ng mL-1)
%RSD A
(injection)
%RSDdrift-time
(injection)
%RSD A
(derivatization)
100 ng mL-1 (N = 5) 10 µg mL-1 (N = 4)
α-ES 4 5.1 0.9 1.9
β-ES 6 6.8 0.5 6.4
3α-AN 5 12.2 1.2 3.6
3β-AN 18 4.3 1.8 3.5
17β-T 15 7.3 0.8 4.3
17α-T 22 5.8 0.8 4.8
4.4 UHPLC-APPI-MS IN THE ANALYSIS OF VITAMIN D
AND OXYSTEROLS OF BRAIN AND CELL LINE
SAMPLES
Two UHPLC-APPI-based methods were developed for the simultaneous
analysis of several oxysterols and vitamin D derived compounds in biological
samples. First, the developed UHPLC-APPI-MS/MS method was successfully
adapted to the analysis of mouse brain samples and to cell line samples. Non-
stressed cell line samples were compared to cell line samples that had been
exposed to oxidative stress and which were thus overexpressing alpha-synu-
clein (α-syn) aggregates (Parkinson’s disease aggregates). Furthermore, the
performance  of  the  UHPLC-APPI-MS/MS method  was  compared  to  that  of
the other method (UHPLC-APPI-HRMS) in the analysis of cell line samples.
4.4.1 METHOD DEVELOPMENT AND VALIDATION
The  APPI-MS  spectra  show  abundant  protonated  molecules  ([M  +  H]+)
and/or  fragment  ions  that  had  been  formed  by  the  loss  of  one  ([M  +  H  -
H2O]+),  two  ([M  +  H  -  2H2O]+)  or  three  ([M  +  H  -  3H2O]+) water mole-
cule(s).  Based on the MS spectra,  the most abundant precursor ions for the
SRM experiments were chosen in order to maximize the sensitivity. MS/MS-
spectra were acquired and product ions for the SRM experiments were cho-
sen according to highest intensity and optimal selectivity.
The UHPLC method showed good chromatographic performance (Figure
13) with plate numbers and tailing factors within acceptable values (~ 40000
and < 1.5, respectively). Although the resolution was insufficient to achieve
baseline separation of all the analytes, the co-eluting analytes could be sepa-
rated  by  MS/MS.  As  an  exception,  the  isomers  7α-OH-Chl  and  7β-OH-Chl
could not be separated from each other with sufficient resolution. Addition-
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ally,  the MS/MS spectra of  these two compounds are similar,  and therefore
these isomers were quantified together.
The  quantitative  performance  of  the  UHPLC-APPI-MS/MS  system  was
evaluated with respect to LOD, linearity (R2), intra-day repeatability and in-
ter-day  repeatability  (Table  18).  The  LODs  (at  S/N  ≥ 3)  were  below  2.5  ng
mL-1 for  all  compounds  except  for  24-OH-Chl  (LOD  =  25  ng  mL-1), which
indicated good sensitivity. Calibration curves and intra-day and inter-day
repeatabilities were determined using analyte to internal standard (ISTD)
peak-area ratios (the ISTDs were d3-D3 for D2, D3, DESMO and 7-DHYD, and
d6-27-OH-Chl for 1α,25-OH-D3, 25-OH-D3, 24-OH-Chl, 27-OH-Chl, 22-OH-
Chl, 7α-OH-Chl, 7β-OH-Chl and 7-OXO). The calibration curves were deter-
mined within concentration range of 0.5-1000 ng mL-1 using  at  least  six
measuring points and linear regression with 1/x weighting. The coefficients
of determination (R2) were better than 0.998 for all of the compounds, which
indicated that the method is linear over a broad range for all of the analytes.
Seven  replicate  injections  were  carried  out  using  a  100  ng  mL-1 standard
sample for the intra-day repeatability studies. The %RSDs were below 0.11%
for the retention times, and below 5.89% for the analyte/ISTD peak area ra-
tios.  A 100 ng mL-1 standard sample was prepared on five consecutive days
and seven replicate injections were made from each sample for the inter-day
repeatability  studies.  The  %RSDs  were  less  than  0.68%  for  the  retention
times and less than 16.83% for the analyte/ISTD peak area ratios. The accu-
racies were well within the general range of 80-120%. These results indicate
acceptable repeatability and accuracy of the method.
A  UHPLC-APPI-HRMS  method  was  used  as  a  confirmatory  method  for
the analysis of selected oxysterols and for the identification of other possible
oxysterols in cell line samples. Therefore, the quantitative performance of the
method was evaluated only with respect to the LODs and linearity (R2) (Table
19). The LODs (at S/N ≥ 3) were 5 ng mL-1 for all of the compounds, which
indicated that the UHPLC-APPI-MS/MS method provides slightly better sen-
sitivity for most of the analytes compared to the corresponding values for the
UHPLC-APPI-HRMS method. Calibration curves were determined using the
analyte/ISTD (d6-27-OH-Chl) peak area ratios and linear regression with 1/x
weighting. The measuring range was 10-500 ng mL-1 (six measuring points)
or 20-500 ng mL-1 (five measuring points) depending on the analyte. The
coefficients of determination (R2) exceeded 0.991 for all of the compounds
and the accuracies were within the general  range of  80-120%. These results
indicate good linearity of the method. The accurate masses of the compounds
were measured showing errors less than 3 ppm.
59
Figure 13 SRM chromatograms of the analytes in a 100 ng mL-1 standard sample analysed by
UHPLC-APPI-MS/MS.
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Table 18. Limits of detection (LODs), limits of quantitation (LOQs, determined at S/N ≥ 10), coefficients of determination (R2), retention times (tR), intra- and
inter-day repeatabilities of retention times (%RSDinj_tR and %RSDinter_tR) and intra- and inter-day repeatabilities of peak areas (%RSDinj_A and %RSDinter_A) for the
analytes measured using the UHPLC-APPI-MS/MS method.
Analyte LOD/LOQ(ng mL-1)
R2/range
(ng mL-1)
tR
(min)
%RSDinj_tR
(N = 7)
%RSDinj_A
(N = 7)
%RSDinter_tR
(N = 35, 5 × 7)
%RSDinter_A
(N = 35, 5 × 7)
1α,25-OH-D3 0.5/1.0 0.9992/0.5-1000 3.50 0.11 5.89 0.68 16.83
25-OH-D3 2.5/2.5 0.9993/2.5-1000 5.38 0.09 2.87 0.64 15.89
24-OH-Chl 25/100 0.9989/25-500 6.07 0.08 6.16 0.58 5.73
27-OH-Chl 1.0/5.0 0.9990/ 1-1000 6.56 0.07 4.48 0.56 5.01
22-OH-Chl 2.5/5.0 0.9995/2.5-1000 6.76 0.00 3.38 0.58 4.87
7α-OH-Chl +
7β-OH-Chl 2.5/2.5 0.9996/2.5-500
9.61 +
9.72
0.00 5.64 0.53 +
0.52
6.81
7-OXO 1.0/1.0 0.9996/1-500 9.97 0.00 3.47 0.51 11.74
D2 1.0/2.5 0.9994/1-1000 12.52 0.00 3.21 0.46 4.03
D3 1.0/2.5 0.9992/1-500 12.72 0.00 1.96 0.43 4.45
DESMO 1.0/2.5 0.9989/1-500 13.24 0.03 2.28 0.43 11.74
7-DHYD 1.0/5.0 0.9988/1-1000 13.65 0.03 2.67 0.45 4.78
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Table 19. Limits of detection (LODs), limits of quantitation (LOQs, determined as S/N ≥ 10), coefficients of determination (R2), exact and accurate masses of
the analytes measured using UHPLC-APPI-HRMS.
Analyte
(detected ion)
LOD
(ng mL-1)
LOQ
(ng mL-1)
R2
range (ng mL-1) Formula Exact mass
Accurate
mass
Error
(ppm)
24-OH-Chl
([M+H-2H2O]+)
5 20
0.9947
20-500 C27H43 367.3365 367.3367 0.54
27-OH-Chl
([M+H-H2O]+)
5 10
0.9959
10-500 C27H45O 385.3470 385.3477 1.82
7α-OH-Chl
([M+H-2H2O]+)
5 20
0.9962
20-500 C27H43 367.3365 367.3367 0.54
7β-OH-Chl
([M+H-2H2O]+)
5 20
0.9955
20-500 C27H43 367.3365 367.3367 0.54
7-OXO
([M+H]+) 5 20
0.9966
20-500 C27H45O2 401.3420 401.3432 2.99
7-DHYD
([M+H-2H2O]+)
5 10
0.9907
10-500 C27H43 367.3365 367.3367 0.54
DESMO
([M+H-2H2O]+)
5 20
0.9953
20-500 C27H43 367.3365 367.3367 0.54
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4.4.2 FEASIBILITY OF THE METHODS IN THE ANALYSIS OF
BIOLOGICAL SAMPLES
The feasibility of the UHPLC-APPI-MS/MS method for the analysis of vita-
min D related compounds and oxysterols  in biological  samples was demon-
strated by analyzing six mouse brain samples and eight human neuroblas-
toma cell line samples. Non-stressed cell line samples were compared to cell
line samples that had been exposed to oxidative stress and thus were overex-
pressing alpha-synucelin (α-syn) aggregates (Parkinson’s disease aggre-
gates). The analytes were identified according to the following criteria: the
variation of the intensity ratios of the monitored product ions was less than
15% and the variation of  the retention times was less than 0.25% compared
to the standard sample.  The feasibility  of  the UHPLC-APPI-HRMS method,
on the other hand, was demonstrated by analyzing oxysterols in non-stressed
and  stressed  cell  line  samples.  The  analytes  were  identified  using  a  0.25%
retention time window and a 25 mDa mass window.
Seven of the selected analytes were found in the mouse brain samples
(Table 20). The most abundant oxysterol in all of the brain samples was 24-
OH-Chl,  which  was  detected  at  a  high  concentration  (1.0-1.6  ×  105 ng  g-1).
This  r5esult  could  be  due  to  24-OH-Chl  being  synthesized  in  the  brain  di-
rectly from cholesterol by CYP46 catalyzed reactions and only 20% of which
is transported into the general blood flow across the blood-brain barrier.79,184-
186 DESMO and 27-OH-Chl were also detected in the brain samples at  rela-
tively  high  concentrations  (8.7-12.3  ×  103  ng  g-1 and  90-210  ng  g-1, respec-
tively), which agrees with other studies.79,187-189 27-OH-Chl  is  formed  from
cholesterol in an enzymatic reaction that is catalyzed by sterol 27-hydrox-
ylase  and  it  is  further  metabolized  by  the  same  enzyme  to  3β-hydroxy-5-
cholestenoic acid.46,190,191 This cholestenoic acid is metabolized in a oxysterol
7α-hydroxylase catalyzed reaction to the metabolite 7α-hydroxy-3-oxo-4-
cholestenoic  acid,  which  is  efficiently  transferred  from  the  brain  to  the  cir-
culation  across  the  blood  brain  barrier.  This  could  be  the  reason  for  the
higher concentrations of 24-OH-Chl in the mouse brains compared to 27-
OH-Chl.188 7α-OH-Chl/7β-OH-Chl (103-136 ng g-1) and 7-OXO (~ 60 ng g-1)
were also detected in the mouse brain samples. These compounds have pre-
viously been identified in human brain samples.189,192 One noteworthy ana-
lyte, namely 25-OH-D3,  was detected in all of the brain samples at low con-
centrations (~4 ng g-1) using SRM transitions of m/z 401→m/z 105 and m/z
133. The finding was also analyzed using, SRM transitions of m/z 383 ([M +
H - H2O]+) → m/z 105 and m/z 133. The identification criteria were fulfilled
in  both  analyses,  thus  the  detection  of  25-OH-D3  in  mouse  brain  samples
was confirmed for the first  time with relatively high reliability  although the
ion chromatograms are quite noisy (Figure 14).
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Table 20. Concentrations of the analytes found in the mouse brain by UHPLC-APPI-MS/MS.
Sample
Compound (ng g-1)
25-OH-D3 24-OH-Chl (× 103) 27-OH-Chl 7α- & 7β-OH-Chl 7-OXO DESMO (× 103)
1 3.40 1.00 89.7 136 75.9 8.71
2 3.44 1.20 130 104 53.8 12.3
3 3.11 1.19 152 108 59.3 9.33
4 3.84 1.21 145 108 56.7 9.54
5 3.76 1.59 209 106 56.3 10.0
6 5.22 1.40 204 132 62.4 7.95
Figure 14 Overlaid SRM-chromatograms of the detected 25-OH-D3 in a standard sample and in a mouse brain sample.
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Four  oxysterols  (24-OH-Chl,  7α-/7β-OH-Chl,  7-OXO and DESMO) were
identified  in  the  cell  line  samples  and  their  concentrations  were  in  good
agreement  with  previous  studies  (Table  21  and  Table  22).46 The concentra-
tions  of  7α-/7β-OH-Chl  and  7-OXO were  more  than  tenfold  in  the  stressed
cell line samples than those of the non-stressed samples. This indicates that
these  oxysterols  are  readily  formed  by  the  oxidation  of  cholesterol  in  the
stressed cell line samples. DESMO was also detected in all of the cell line
samples. Interestingly, the concentration of this compound is half to one-
third in the stressed samples to that  of  the non-stressed samples.  This  may
be due to further oxidation of the double bond at the side chain of this com-
pound.  Similar  results  have  been  observed  by  other  research  groups  as
well.193,194 Additionally, 24-OH-Chl was detected in the non-stressed cell line
samples at concentrations below LOQ when the UHPLC-APPI-MS/MS
method was used. Therefore, a reliable quantification of this compound could
not  be  achieved.  On  the  other  hand,  24-OH-Chl  was  not  detected  in  the
stressed cell line samples.
Table 21. Concentrations of the analytes found in cell line samples by UHPLC-APPI-
MS/MS.
Sample
Compound (ng mL-1)
24-OH-Chl 7α- & 7β-OH-Chl 7-OXO DESMO
WT 1 < LOQ 75.5 146 40
WT 2 < LOQ 29.3 39.7 27
WT 3 < LOQ 20.9 32.9 24
WT 4 < LOQ 24.9 42.7 28
WT 5 < LOQ 28.3 41.4 27
WT 6 < LOQ 26.6 43.1 28
Stressed WT 1 < LOQ 274 919 6.9
Stressed WT 2 < LOQ 316 1070 7.7
Stressed WT 3 < LOQ 326 1080 9.1
A30T 1 < LOQ 25.3 37.2 20
A30T 2 < LOQ 23.1 33.3 20
A30T 3 < LOQ 25.4 36.1 21
Stressed A30T 1 < LOQ 398 976 3.2
Stressed A30T 2 < LOQ 290 715 2.7
Stressed A30T 3 < LOQ 293 715 2.5
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Table 22. Concentrations of the analytes found in cell line samples by UHPLC-APPI-
HRMS.
Sample
Compound (ng mL-1)
7α-OH-Chl 7β-OH-Chl 7-OXO DESMO
WT 1 10.8 41.5 103 16
WT 2 14.2 46.0 125 21
WT 3 21.6 57.1 142 19
Stressed WT 1 234 1000 1970 4.0
Stressed WT 2 187 813 1630 -
Stressed WT 3 301 1080 2120 5.9
A53T 1 22.9 44.2 105 14
A53T 2 81.8 111 266 20
A53T 3 20.8 38.7 96.7 18
Stressed A53T 1 286 794 1770 4.6
Stressed A53T 2 288 771 1760 -
Stressed A53T 3 263 731 1650 -
The data produced by UHPLC-APPI-HRMS can also be used in identify-
ing non-targeted oxysterols and vitamin D related compounds. In this study
four  additional  compounds,  the  concentrations  of  which  were  higher  in  the
stressed cell line samples compared to the non-stressed cell line samples,
were identified by the UHPLC-APPI-HRMS method. These four compounds
were  identified  as  oxysterols  based  on  data  that  met  the  following  criteria:
the collision induced spectra (CE = 30 eV) of these compounds showed sim-
ilar types of fragmentation as the selected oxysterols, the exact masses corre-
sponded to the elemental composition of oxysterols, and the retention times
were in the same range as the retention times for the selected oxysterols. The
data  did  not,  however,  allow  the  characterization  of  the  exact  structures  of
these compounds.
In conclusion, two UHPLC-APPI-MS methods were developed and quali-
fied for the simultaneous analyses of several oxysterols and vitamin D related
compounds in the mouse brain and cell line samples. The concentrations of
the detected oxysterols in the brain samples were consistent with earlier
studies and additionally, 25-OH-D3 was identified and quantified in mouse
brain samples for the first time. The concentrations of two of the compounds
(24-OH-Chl  and  DESMO)  were  over  the  linearity  range  of  the  calibration
curve. Thus, the determined concentrations of these compounds are not ex-
act,  but for the purpose of  this  study the exact  concentrations of  these ana-
lytes were not considered relevant and therefore no further measurements
(for example after diluting the samples) were made. Oxysterols were detected
in the brain samples, therefore they were also analyzed in cell line samples
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used as a model to study the formation of α-syn aggregates related to Parkin-
son’s disease. Here oxidative stressed cell line samples that overexpress α-
syn  were  compared  to  non-stressed  samples.  The  concentrations  of  the
oxysterols differed remarkably in the oxidative stressed cell line samples
compared  to  the  non-stressed  controls.  These  results  show  that  the  role  of
oxysterols in the formation of α-syn aggregates cannot be ruled out and fur-
ther studies are needed for determining and elucidating the roles of oxyster-
ols in brain function.
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5 SUMMARY AND CONCLUSIONS
The overall aim of this research was to develop different mass spectrometry
based methods for the analysis of steroids, vitamin D related compounds and
oxysterols,  and to apply the developed methods in the analysis  of  biological
samples.
It  was  shown  (I),  that  the  in-house-built  heated-nebulizer  microchip  in
APPI mode (µAPPI) combined to a capLC-MS/MS is feasible for the analysis
of anabolic steroids in human urine samples. The quantitative performance
of the developed method was evaluated with respect to the limits of detec-
tion, linearity and repeatability, and the results show good quantitative per-
formance of  the method.  Full  validation of  the method was not carried out,
since quantitative analysis is seldom necessary in doping analysis. The ad-
vantage  of  µAPPI  over  commercial  APPI  sources,  is  the  possibility  of  using
low  flow  rate  capLC,  which  is  not  possible  with  commercial  APPI  sources
since they require flow rates in as high as 200 µL min-1 for adequate ioniza-
tion of the analytes. The advantage of using capLC, on the other hand, is that
the ionization efficiency can be improved since the lower flow rate produces a
very  narrow  gas  jet,  which  provides  high  ion  transmission  into  the  mass
spectrometer. Additionally the use of capLC results in decreased eluent, rea-
gent, and nebulizing gas consumption thus decreasing analysis costs and
environmental load. Therefore, it can be concluded that capLC-µAPPI-
MS/MS is a promising tool for bioanalysis.
The feasibility of a commercial microfluidic-based HPLC-Chip/MS system
for  the  analysis  of  oxime-derivatized  steroids  was  compared  to  a  conven-
tional  narrow-bore  LC-MS  system  in  study  II.  Both  methods  showed  good
linearity and good quantitative and chromatographic repeatability. It was
also shown, that  the sensitivity of  the HPLC-Chip/MS system was about 50
times better that of the sensitivity of the conventional narrow-bore LC-MS
system if  the  limits  of  detection  are  presented  as  injected  sample  amounts.
The sensitivity of the conventional LC-MS system is, however, slightly better
when the limits of detection are presented as concentrations in the sample. It
follows that the use of the HPLC-Chip/MS system is advantageous when the
sample volume is limited, which often is the case in the analysis of biological
samples.
A  comparison  of  the  analysis  of  oxime-derivatized  steroids  using  the
HPLC-Chip/MS system with that  of  the analysis  of  non-derivatized steroids
in  study  II,  found  that  the  sensitivity  with  the  oxime  derivatives  were  ap-
proximately one order of magnitude higher than those of the non-derivatized
steroids.  This result  is  in agreement with previous studies and it  is  because
the basic character of the oxime group significantly improves the ionization
efficiency in ESI. Nevertheless, the feasibility of the HPLC-Chip/MS system
for the analysis of non-derivatized steroids in mouse plasma samples was
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successfully demonstrated for the selected steroids and showed steroid con-
centrations within the same range as previously reported. This information is
useful,  since  oxime  derivatization  can  be  applied  only  for  ketosteroids  and
thus the development of a universal method for steroids by means of oxime
derivatization is impossible. Nevertheless, the method should be further
validated with respect to repeatability and regarding possible matrix effects.
Now  the  matrix  effect  was  only  tested  by  injecting  blank  artificial  plasma
samples  prior  and  after  the  spiked  artificial  plasma  samples.  Post-column
infusion  could  unfortunately  not  be  made  with  the  HPLC-Chip/MS  system
since the chip is inserted in the Chip Cube and no additional connections can
be made between the column and the mass spectrometer. Additionally, an-
other type of HPLC-Chip should be chosen for future work, since the particle
size (5 µM) and the pore size (300 Å) in the column used for this study were
not small enough. This might solve the problem with wide peaks and co-elu-
tion of analytes and thus it would provide better selectivity of the system (es-
pecially regarding isomeric steroids).
The  work  presented  in  publication  III  demonstrates  the  feasibility  of
TWIM-MS  for  separating  steroid  isomers  under  different  drift  gas  condi-
tions. The final method used the derivatization of the steroid isomers with p-
toluenesulfonyl  isocyanate,  since  the  collision  cross  sections  of  the  native
steroid  isomers  appeared  to  be  too  similar  for  successful  separation  by
TWIM-MS.  The  derivatization  increased  the  collision  cross  section  of  the
isomers and/or the strength of their ion/molecule interactions with the drift
gas and hence it  improved their  separation in the ion mobility  cell.  As a re-
sult, the steroid isomers could be successfully separated and showed almost
baseline resolution. This is a very important result for steroid analysis (e.g.
within doping analysis) since TWIM-MS can be performed on a millisecond
time-scale. Therefore, this method can improve immediate separation, char-
acterization and quantification of α/β steroid isomers. Unfortunately the
separation of  the steroid isomers requires the derivatization step,  which in-
creases the analysis time. Nevertheless, the derivatization step can be done in
parallel with the analysis step and thus high throughput is still possible with
the developed TWIM-MS method. The sensitivity of the developed method
might cause problems for the analysis of some biological samples where the
background signal caused by the matrix is high (for example urine samples).
This problem could be solved, though, by combining the TWIM-MS method
with a UHPLC-MS/MS method whenever additional high sensitivity is
needed.
In publication IV, a UHPLC-APPI-MS/MS method was developed for the
simultaneous  quantitative  analysis  of  several  oxysterols  and  vitamin  D  re-
lated  compounds  in  the  mouse  brain  and  cell  line  samples.  The  results
achieved for the cell line samples were confirmed by a UHPLC-APPI-HRMS
method. Seven oxysterols could be quantified from mouse brain samples by
the UHPLC-APPI-MS/MS method. The results were consistent with earlier
findings obtained by LC-ESI-MS methods. Interestingly, 25-OH-D3 was also
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identified and quantified for the first time in mouse brain samples. Addition-
ally, both oxidative stressed and non-stressed cell line samples were ana-
lysed. Four of the selected compounds could be identified and quantified at
differing concentrations, depending on whether the sample had been oxida-
tive  stressed  or  not,  by  the  UHPLC-APPI-MS/MS  and  the  UHPLC-APPI-
HRMS  method.  Data  acquired  by  the  UHPLC-APPI-HRMS  method  also
showed  the  presence  of  four  non-targeted  oxysterols  in  all  of  the  cell  line
samples within the same concentration range as the targeted analytes. These
results  suggest,  that  the  role  of  oxysterols  in  the  formation  of  α-syn  aggre-
gates related to Parkinson’s disease cannot be rule out. Consequently, further
studies  are  needed  for  understanding  the  actual  roles  of  oxysterols  in  brain
function.
The advantage of  using APPI in publication IV instead of  the more com-
mon ESI is  that  the time consuming and laborious derivatization procedure
usually required in ESI is not needed in APPI to achieve adequate ionization
efficiency. Therefore, APPI provided significantly faster analyses for the se-
lected compounds compared to ESI. Thus the developed UHPLC-APPI-MS
methods are well  suitable for further studies related to role of  oxysterols  in
brain function.
In  conclusion,  the  work  summarized  in  this  thesis  presents  several  new
methods for the analysis of selected lipids in biological samples. Routine la-
boratories  e.g.  within  forensic  and  doping  analysis  all  over  the  world  con-
stantly need new highly sensitive and selective methods. Additionally, the
methods should be easy and fast, and they should have lower analyses costs
and decreased environmental impact. Mass spectrometry based analysis of
lipids is  more problematic  compared to the analysis  of  more polar analytes,
therefore the importance of the development of new methods within the field
of  lipid  analysis  is  highly  important.  Additionally,  exact  knowledge  of  the
importance of lipids in biological systems such as the human brain, in which
minimal changes in concentration levels might affect the function of the en-
tire system would be a boon to neurological research. This is due to the fact
that  the  concentrations  of  many  of  the  studied  compounds  might  be  below
the detection limits of the current analytical methods. Some of the methods
presented here could be directly implemented in routine laboratories, while
some would need additional optimization for example regarding validation of
the methods, detection limits (especially the often required sensitivity of 1
pM  for  steroid  analysis  remain  a  challenge)  and  total  analysis  times.  Espe-
cially the sensitivity issues should be addressed before implementing these
methods in routine laboratories. Nevertheless, some of the presented meth-
ods (I and IV) show sensitivities and qualification parameters, which are well
comparable  to  previously  presented  methods  (Table  1)  and  thus  applicable
for  routine  analysis.  All  in  all,  the  new information  presented  in  this  thesis
can be important for routine laboratories in the future.
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APPENDIX: ORIGINAL PUBLICATIONS I-IV
Some minor  mistakes  in  the  original  publications  were  found when writing
this thesis. These mistakes have been corrected in the thesis, and are as fol-
lows:
· Original  publication  I,  Table  4:  the  linear  range  and  number  of
measuring points for NAN are wrongly written. The correct values are
1-250 ng mL-1 for the linear range (this is written correctly in the text
on page 963) and 9 measuring points.
· Original  publication  I,  Sections  “Abstract”  (page  958)  and  “Results
and discussion” (page 963) and Table 4:  the term “correlation coeffi-
cient” is wrongly used in combination with the abbreviation R2. The
correct term for this abbreviation is “coefficient of determination”.
· Original  publication II,  Section 2.5 (page 117):  eluent A and eluent B
have been mixed up when explaining the gradient for non-derivatized
steroids. The correct eluent are (A) 50 mM NH4Ac (pH 4.5):H2O (1:9,
v/v) and (B) 50 mM NH4Ac (pH 4.5):MeOH:ACN (1:3:6, v/v/v).
· Original publication II, Sections 3.1 (page 119) and 3.2 (page 119), and
Tables  1  and  2:  the  term  “correlation  coefficient”  is  wrongly  used  in
combination with the abbreviation R2. The correct term for this abbre-
viation is “coefficient of determination”.
